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ABSTRACT 
CXCR4 is a chemokine receptor that has been linked to several disease related pathways 
including: HIV-1 proliferation, autoimmune disorders, inflammatory disease and cancer 
metastasis. The interaction of the C-X-C chemokine receptor type 4 (CXCR4) with C-X-C 
chemokine ligand 12 (CXCL12) plays a key role in triggering these disease related pathways. 
Various antagonists for these receptors have been synthesized and tested, but many are not useful 
clinically either because of toxicity or poor pharmacokinetics. Some of the most extensive CXCR4 
antagonist libraries stem from a class of compounds, p-xylyl-enediamines, which all feature a 
benzene ring as the core of the compound. This work focuses on the design and synthesis of a new 
class of compounds that show potential as CXCR4 antagonists by using heterocyclic aromatic 
rings (2,6-pyridine, 2,5-furan, 2,5-pyrazine and 3,4-thiophene) as the core of the scaffold. After 
synthesis, these analogues were probed through a variety of assays and techniques by our 
collaborators in the Shim lab at Emory University including: preliminary binding assays, Matrigel 
invasion assays, carrageenan mouse paw edema tests, and in silico analysis. In silico analysis also 
probed 2,5-thiophene-based analogues previously synthesized. This work has produced the 
beginnings of a new library of CXCR4 antagonists and has identified fifteen hit compounds that 
are promising leads for further testing and modification. 
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1     INTRODUCTION 
 
This work is centered around synthesizing and analyzing small molecules to disrupt the 
interaction between CXCR4, a protein receptor, and CXCL12, a ligand. This interaction triggers 
many pathways in the body—including cancer cell metastasis and inflammation. The precedence 
in mitigating these diseases will be explained in two parts below. 
 
1.1 Cancer 
A formidable foe and wily enemy, cancer has been a troubling adversary to a many people 
from all socio-economic and racial backgrounds. Researchers, doctors, grocers, artists, students, 
entrepreneurs, sons and daughters—none are immune to cancer. For the year 2014, cancer was 
estimated to have claimed the lives of 585,720 American citizens, which is 1.3 times the population 
of Atlanta, Georgia. Furthermore, an estimated 1.6 million people were diagnosed with cancer in 
2014 in the United States. According to the CDC, 7.6 million people—just over the population of 
Hong Kong—worldwide die from cancer.1 As intimidating as cancer is in the world today—as the 
second leading cause of death,2 cancer has been a known disease for centuries, with evidence of 
tumors in the bones of mummies from 1600 BC and descriptions of tumor removals in ancient 
Egyptian inscriptions.3 
Cancer is a broad and multi-faceted disease stemming from numerous mutations from the 
host’s DNA genome. Each mutation has the possibility of giving the cancer cell a method of 
escaping the body’s immune system or an advantage in order to gain more resources from the 
surrounding area to thrive. Because of this, cancer is always different from person to person, and 
possibly even from tumor to tumor in a single host’s body. This makes the treatment of cancer 
5 
difficult—not only are there multiple mutations that can cause a tumor to thrive in a person’s body, 
but breast cancer cells from two individuals might not respond to the same medicines or treatments.  
Cancer occurs when healthy cells fall out of the healthy cell cycle—which includes cell 
death after a certain number of divisions. Cancerous cells continue to grow and divide and do not 
undergo programmed cell death.3 Mutated DNA causes these deviations from the healthy cell 
cycle. In ordinary cell replication, mutations are not extremely rare; however, organisms contain 
enzymes and proteins that check DNA for mutations as well as special enzymes capable of fixing 
any mutated strands by replacing the mutated parts before the cell division is completed and normal 
daughter cells are still formed. DNA mutation can become the devastating disease we know as 
cancer when mutations slip by the body’s processes that aim to prevent the mutations during cell 
division. Mutations can be triggered and caused by a number of factors. Mutated DNA can be 
given from parents to a child, or environmental factors can cause mutations in a person’s DNA.3 
Fortunately, cancer survival rates have increased for the past thirty years. In 1975, newly 
diagnosed cancer patients had a 48.9% survival rate over a five-year. In 2010, the five-year survival 
rate rose to 68.3%.4 This increased survival rate can be attributed to advances in medicine and 
novel strategies to combat cancer. 
X-rays were discovered in 1896 and quickly became routine in cancer treatment and 
diagnosis in only three years. New technologies such as ultrasound, computed tomography, 
magnetic resonance imaging and positron emission tomography have all played an important role 
in cancer diagnosis and treatment—providing lower risk and non-invasive methods of analyzing 
tumors. Better diagnostic tools as well as new methodologies to destroy or remove them via lasers 
have improved surgery procedures. Chemotherapy agents have been synthesized and research over 
the years has been effective in reducing side effects. Hormonal and immunotherapy are also paving 
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the way for potential anti-cancer vaccines and drugs that try to reprogram a cancer cells to stop 
growing and undergo cell death.3 These new technologies and innovations have changed the fight 
against cancer for the better. For most cancer patients, multiple treatment strategies are used to 
target the cancer. This is because cancer is able to proliferate through multiple pathways. 
 
1.1.1 Hallmarks of Cancer 
Robert Weinberg and Douglas Hanahan proposed the ‘Hallmarks of Cancer,’ which are the 
fundamental, distinguishing characteristics that transform normal cells into cancerous cells.5 
Cancer is different for every person and classification by treatment would prove to be difficult. 
Cancers can grow in different parts of the body and sometimes can metastasize to travel to other 
parts of the body. The hallmarks are defined as ‘acquired functional capabilities that allow cancer 
cells to survive, proliferate and disseminate.’ Cancerous cells can acquire these hallmarks in 
different ways at different times and in different orders. The original six hallmarks of cancer are: 
the ability to sustain proliferative signaling, the ability to evade growth suppressors, the ability to 
activate invasion and metastasis, the ability to enable replicative immortality, the ability to induce 
angiogenesis or new blood vessel generation and the ability to resist cell death. Four new 
characteristics have recently been added to the list. There are two abilities—the ability to 
deregulate cellular energetics and the ability to avoid immune destruction. The final two have been 
called ‘enabling characteristics’ which are tumor-promoting inflammation and genome instability 
and mutation.5 The original six hallmarks of cancer are below in Figure 1. 
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Figure 1: This picture shows the six original hallmarks of cancer5. Reprinted from Cell, Volume 
144, Issue 5, Hanahan, D., Weinberg, R. A. Hallmarks of cancer: the next generation, page 647, 
2011, with permission from Elsevier. 
 
Various cancers can possess various hallmarks, or combination of hallmarks. As hallmarks 
are mutated abilities to give cancer extra functionality, a common strategy to treat cancer is to 
address the various hallmarks. When undergoing chemotherapy, cancer patients are prescribed 
several drugs—each often with a different function—to attack specific aspects or hallmarks of 
cancer. Chemotherapy can be combined with other cancer treatment strategies such as radiation or 
surgery to achieve a higher success rate of eliminating the cancer.  
 
1.2 Inflammation 
Irritable Bowel Disease (IBD) is quickly becoming a global concern; however, the 
incidences of IBD vary by location. An estimated 1.2 million Americans6 have been diagnosed 
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with IBD, and between 2.5 and 3 million people in Europe.  Another concerning feature is that as 
nations become industrialized, incidences of IBD increase.7 Even though 0.5% of the western 
world has been diagnosed with IBD,7 incidences are expected to rise exponentially over the next 
ten years.8 IBD is a low mortality disease; therefore, even with a steady incidence rate, the amount 
of people affected is compounded.  
Higher rates of IBD lead to higher costs to treat this disease. Immunosuppressive treatment 
plans can cost upwards of $25,000 annually.8 Innovation is needed to prepare for a future where 
increasing members of our population need to be treated for this disease and lower the cost of said 
treatments. 
IBD is comprised of several different diseases—including Crohn’s disease (CD) and 
ulcerative colitis (UC)—which are environmentally triggered and appear in genetically susceptible 
individuals. The trigger causes an unusual immune response to the individual’s intestinal flora 
resulting in gastrointestinal inflammation.9-10 Individuals with IBD have exhibited altered 
chemokines and receptors in their epithelial cells, which could disrupt the body’s recognition of 
their gut bacteria. Not only are individuals with IBD, unable to recognize enteric microbiota, but 
it is also possible that they are unable to regulate the amount of pro-inflammatory chemokines that 
are sent as the immune response.11-12  
Rheumatoid Arthritis (RA) is an auto-inflammatory disease that affects 1.5 million people 
in the United States with about 5-500 new diagnoses per 100,000 people each year.13-14 RA 
symptoms usually appear in women between the ages of 40 and 50 and a bit later for men.15  Men 
and women from diverse ethnicities and races can all suffer from RA.16 Even though men and 
women can both be diagnosed with RA, three times as many women are living with RA than 
men.17  
9 
There is no one test to diagnose RA as the disease seems to both have a genetic component 
and environmental triggers.14 Because of this, RA is diagnosed by the symptoms displayed.18 RA 
is characterized as inflammation in the joints caused by the immune system attacking the joint 
tissue. The inflammatory response causes the synovium to become thick, and leads to swelling of 
the joints. As this continues, the inflamed synovium degrades the cartilage and bone and weakens 
the surrounding muscles, tendons and ligaments.18 This inflammatory response occurs in the joints 
primarily; however, organs can be inflamed as a symptom of RA.19 There is no cure for RA, 
however, management and treatment are more successful when it is treated early and 
aggressively.20 
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2     DESIGN AND SYNTHESIS OF SMALL MOLECULE HETEROCYCLIC 
AROMATIC-BASED CXCR4 MODULATORS 
 
2.1 Background 
CXCR4 is a chemokine receptor that has been linked to various disease pathways 
including: HIV-1 proliferation, autoimmune disorders, inflammatory disease and cancer 
metastasis.21-22 The interaction of the C-X-C chemokine receptor type 4 (CXCR4) with C-X-C 
chemokine ligand 12 (CXCL12) plays an important role in cancer metastasis and inflammation.23 
Various antagonists for these receptors have been synthesized and tested, but many are not useful 
clinically either because of toxicity or poor pharmacokinetics.22, 24 This work focuses on the design 
and synthesis of a new class of compounds that show potential as CXCR4 antagonists by using 
aromatic heterocyclic rings as the core of the compound.  
 
2.1.1 Chemokines and CXCR4 
Cytokines are small proteins (5-20 kDa) involved cell signaling. A large variety of cells 
(endothelial cells, macrophages, T cells, B cells) produce these proteins for different functional 
purposes. Chemokines are cytokines that chemoattract cells to areas of inflammation by binding 
to G protein coupled receptors (GPCRs), chemokine receptors, and creating a chemical gradient.25-
27 Chemokines can belong to four different groups, C, CC, CXC, and CX3C. They are named 
based on the location of the first two cystine residues on the N-terminus.28  
11 
 
Figure 2: Structure of CXCR4. Reprinted with permission from Wu, B.; Chien, E. Y. T.; Mol, C. 
D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; Brooun, A.; Wells, P.; Bi, F. C.; Hamel, D. F.; 
Kuhn, P.; Handel, T. M., Cherezov, V.; Stevens, R. C. Structures of the CXCR4 chemokine GPCR 
with small-molecule and cyclic peptide antagonists. Science. 2010. 330, 1066-1071. Copyright 
2010 American Association for the Advancement of Science. 
 
Most chemokines can bind to more than one chemokine receptor and receptors to more 
than one ligand. These chemokines are referred to as promiscuous; however, six of the eighteen 
known chemokine receptors bind to a single chemokine ligand.29 CXCR4 (shown in Figure 2) is 
one of these non-promiscuous receptors. CXCR4 is a seven transmembrane GCPR and has been 
known by a few other names—CD184, LESTR30 and fusin.31 CXCR4 binds exclusively to the 
chemokine ligand, CXCL12 (SDF-1).32-33 CXCL12 has several isoforms in the body and even 
though the alpha isoform is the most prevalent,34 CXCR4 seems to bind to each isoform with 
similar affinities.35   
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Figure 3: Structure of CXCL12. Reprinted with permission from Murphy, J. W.; Yuan, H.; Kong, 
Y.; Lolis, E. J. Heterologous quaternary structure of CXCL12 and its relationship to the CC 
chemokine family. Proteins: Structure, Function, and Bioinformatics. 2009. 78 (5), 1331-1337. 
Copyright 2009 Wiley-Liss, Inc. 
 
Because CXCR4, is involved in many drug and disease pathways like HIV-131 entry and 
cancer metastasis,36 it is one of the most studied chemokine receptors.37 Through knock out mice 
studies, it has been shown that CXCR4 is necessary for neural development and hematopoiesis, 
organogenesis and vascularization in embryos.38-41 CXCR4 has different functions, in line with 
other chemokine receptors, in adults.42 In healthy cells, the interaction between CXCR4 and 
CXCL12 triggers several downstream pathways: mobilization of stem cells,43 inflammatory cells 
and immune cells,44  cell survival,45 gene transcription,46 intracellular calcium modulation,47 and 
cell adhesion.48 
 
2.1.2 CXCR4 Mechanism of Action 
The crystal structure of CXCR4 was first reported in 2007 with the protein bound to a small 
molecule antagonist, IT1t.49 The crystal structure was incomplete, in that some amino acids in the 
N terminus were missing.50 In 2008, an NMR structure of CXCR4’s N terminus in complex with 
CXCL12 was reported and it was able fill in some of the missing in pieces and identify some of 
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the interactions between CXCL12 and CXCR4.51 Unfortunately, there is no crystal structure of 
CXCR4 and CXCL12 bound together. 
CXCL12 binds to CXCR4 in a two-step process. In the first step, the beta sheets, the 50s 
loop (the series of amino acids connecting the last beta sheet to the alpha helix), and N loop (the 
series of amino acids connecting the N terminus to the first beta sheet) of CXCL12 interact with 
the extracellular region on the top of CXCR4.52 The N terminus of CXCR4 then interacts with the 
RFFESH loop (residues 12-17) of CXCL12.51, 53 It has been suggested that this first step causes a 
conformational change in CXCR4 which exposes the binding pocket in the helices.54-55 This allows 
the N terminus of CXCL12 to interact with the residues in the binding pocket near the top of the 
helices of CXCR4.53 The crystal structure of CXCR4 reveals that the binding pocket is larger and 
closer to the extracellular surface compared to other GCPRs.50 
Because of this two-step process, small molecule antagonists may not completely block the 
interactions between CXCR4 and CXCL12. Since the CXCR4/CXCL12 interaction is vital for 
other necessary physiological processes, and ideal antagonist would block some functionality but 
not all function. Particularly, small molecules that block the N terminus of CXCL12 from binding 
in the second step would not block interactions in the first step.56 Key residues involved in the 
second binding site influence signaling and have been identified as ASP97 (ECL2), ASP187 
(TMII), and GLU288 (TMVII).57-58 ASP171, ASP 87 and ASP262 have also been suggested to be 
important binding sites for signaling.59 
 
2.1.3 Drug and Disease Related Pathways of CXCR4 
CXCR4 is a seven transmembrane GPCR, which is embedded in the cell membrane and 
interacts with other proteins from the cell surface.60-62 This receptor was first discovered as a co-
14 
receptor for HIV-1 entry and after more studies were conducted, the other functional 
responsibilities of CXCR4 were uncovered.61-64 CXCR4 selectively binds to the chemokine ligand, 
CXCL1265 and this interaction plays a very important role in the body as knock out mice for both 
of these genes do not survive due to a number of defects in the embryo.61-62 The interaction between 
CXCR4 and CXCL12 triggers downstream pathways that induce inflammation; therefore, over 
expression of CXCR4 has also been linked to inflammatory diseases such as allergic asthma,66 
IBD,67 systemic lupus erythematosus (SLE), atherosclerosis68 and rheumatoid arthritis.69 Lastly, 
the CXCR4/CXCL12 promotes cancer cell metastasis.70  
 
 
Figure 4: Reprinted with permission from Choi, W. T.; Duggineni, S.; Xu, Y.; Huang, Z. W.; An, 
J., Drug Discovery Research Targeting the CXC Chemokine Receptor 4 (CXCR4). J Med Chem. 
2012, 55 (3), 977-994. Copyright 2017 American Chemical Society. 
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Since the CXCR4-CXCL12 axis plays such an important role in these disease related 
pathways, blocking this interaction has become a leading strategy in an attempt to reduce the 
progression of cancer and other inflammatory conditions.71 Several small molecule antagonists 
have had success in blocking this interaction and have been shown to inhibit cancer metastasis, 
HIV-1 entry and have anti-inflammatory activity.72-75 
 
2.1.3.1 CXCR4 and Metastasis 
Migration of cells is normal in the human body.76 The immune system is comprised of cells 
that migrate through the body in order to facilitate healing in infected areas and routine repair and 
upkeep inside the body.76-78 This migration inside the body is made possible by two groups of 
proteins. The first group—chemokines—is comprised of small proteins, which interact with the 
second group of proteins called chemokine receptors.22 In particular, the interaction between the 
chemokine ligand, CXCL12, and the chemokine receptor, CXCR4, plays an important role in 
triggering pathways to facilitate physiological functions.22, 62, 79 The interaction between CXCR4 
and CXCL12 orients hematopoietic stem cells (HSCs), nonhematopoietic tissue-committed stem 
cells (TCSCs), pre-B lymphocytes, t lymphocytes and embryonic stem cells (ESCs) to their 
appropriate sites in the body.76-77, 80-81  
Metastatic cells break from the primary tumor and travel through the body and create 
tumors in other parts of the body.76, 82 Metastatic cancer cells take advantage of the 
CXCR4/CXCL12 signaling interaction in order to migrate through the body in the same way that 
stem cells in the body migrate.70 Many tumors develop hypoxic conditions as it grows due to 
changes in cell vasculature.83 HIF-1 is then activated because of the hypoxia and can promote the 
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expression of CXCR4.84-86 It’s also possible that other growth factors contribute to upregulation 
of CXCR4 because of the increased surface area of the tumor.37 
Over expression of CXCR4 in cancer cells can lead to production of metalloproteases,87-90 
which can degrade membranes, enabling the cells to enter into the blood stream.91 Once 
circulation, these cells migrate to CXCL12 rich sites in the body—i.e. lymph nodes, lung, liver 
and bone marrow.22, 77, 79-80, 92 These cells migrate through chemotaxis, which is a system that pilots 
cells through the body.34 CXCL12, that is secreted by cells diffuses away from their source and 
this creates a gradient. This gradient extends from the CXCL12 rich sites and becomes more dilute 
as distance from the source increases.34 The CXCR4-rich cancer cells will then be guided through 
the gradient to the sites that are CXCL12-rich.93 CXCR4 overexpression triggers integrin activity, 
enabling the cancerous cells to adhere to the surrounding tissue once they migrate.94-96 
Stage IV cancers—metastatic cancers97—usually yield a poor prognosis compared to other 
stages98 and CXCR4 expression on a tumor is used to determine the prognosis for many types of 
cancers including leukemia, breast cancer, prostate cancer, lung cancer and ovarian cancer.60, 62, 76, 
82, 92 As seventy five percent of all cancers over express CXCR4, it is strategic to use CXCR4 
expression as marker in cancer diagnosis and prognosis.60  
Tissue invasion and metastasis is one of the hallmarks of cancer outlined by Weinberg and 
Hanahan.5 Slowing down metastatic cancer could help boost cancer survival rates and keep tumors 
localized for other treatments medicines to work  more effectively. Targeting the CXCR4/CXCL12 
axis to stop metastasis is an alluring tactic because the CXCR4 proteins that are expressed are less 
likely to mutate. The CXCR4/CXCL12 interaction is specific; therefore, if the CXCR4 was 
changed as response to a drug preventing it from migrating, it would likely no longer bind to 
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CXCL12, and still would not be able to migrate. And since the CXCL12 is produced by healthy 
cells, the risk of mutation of the receptor while retaining activity is low. 
 
2.1.3.2 CXCR4 and Inflammation 
CXCR4 and CXCL12 are expressed in healthy intestinal epithelial cells (IEC).99-101 Both 
CXCR4 and CXCL12 are needed for necessary physiological functions including electrolyte 
secretion,102 migration, and upkeep of the epithelial mucosal membrane.103 CXCR4 and CXCL12 
expression, however, are both upregulated in the IEC’s of patients with IBD.67, 104 The presence of 
extra CXCL12 chemoattracts CD45RO+ T cells, which are rich with CXCR4. This interaction 
triggers inflammation in the intestinal membrane and disrupts the intestinal membrane’s 
homeostasis.104 It is possible that blocking the CXCR4, CXCL12 interaction can help mitigate 
intestinal inflammation for patients with IBD. 
In patients with Rheumatoid arthritis, CD+ T cells, neutrophils and macrophages gather 
into the synovial tissue in joints and damage surrounding tissue.105-106 Several studies have 
suggested that the overexpression of CXCR4 in the synovial tissue, recruits the T-cells to gather 
into those areas.72 Furthermore, treatment of  RA in mice with CXCR4 antagonists like 
AMD3100107 and TN14003,108 a peptide antagonist, yield a reduction in inflammation. 
Furthermore, treatment of RA with low-level laser irradiation (LLLI)109 reduces inflammation by 
decreasing the expression of CXCR4 in the affected area. Overexpression of CXCR4 has also been 
documented in the monocytes, neutrophils and B cells of patients with lupus.110 Additionally, 
treatment in mouse models with CXCR4 antagonists have shown reduction of symptoms.111 As 
CXCR4 is a key factor in the inflammatory response and as existing small molecule antagonists 
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have shown to be effective in mitigating symptoms of inflammatory diseases, this sets a 
precedence for the creation of new antagonists. 
 
2.1.4 CXCR4 Antagonists and Modulators 
Since the CXCR4-CXCL12 interaction plays such an important role in these disease related 
pathways, blocking this interaction has become a leading strategy in an attempt to mitigate these 
pathways or even selectively accelerate normal physiological pathways.22 Several small molecule 
antagonists have had success in blocking this interaction and have been shown to inhibit cancer 
growth, inhibit cancer metastasis and have anti-RA activity.23, 112-114 
 Many compounds that have shown potential as CXCR4 antagonists and share the common 
central benzene ring. This class of compounds is called p-xylyl-enediamines. There are several 
other categories of CXCR4 antagonists, shown in Figures 5, 6 and 7, including: cyclic 
pentapeptide-based antagonists, indole based antagonists, quinoline-based antagonists, 
pyrimidine-based antagonists and tetrahydroquinoline-based antagonists;92 however, this work 
focuses only on the p-xylyl-enediamines.  
 
 
Figure 5: General structure for tetrahydroquinoline-based CXCR4 antagonists.92 
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Figure 6: Examples of indole-based,115 cyclic pentapeptide-based,116 quinoline-based,117 and 
pyrimidine-based CXCR4 antagonists.118 
 
 
Figure 7: General Structure for p-xylyl-enediamine-based CXCR4 antagonists. 
 
2.1.4.1 AMD3100 and p-xylyl-enediamines 
One of the first small molecule inhibitors of CXCR4 to show promise was AMD3100.64 
The precursor to this compound was discovered as an impurity that showed anti-HIV activity by 
blocking CXCR4, which is one of the receptors HIV-1 uses to enter the cell. This impurity was 
composed of two cyclam rings connected by an aliphatic chain. Replacing the aliphatic linker with 
a benzene ring increased the potency of the compound—resulting in AMD3100 (Figure 8).119 
Other non-aromatic ring derivatives of AMD3100 were synthesized and tested for activity, but 
only the compounds featuring benzene rings were active.120 
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AMD3100 was the first FDA approved CXCR4 antagonist; however, even though the 
initial purpose for this compound was to block HIV-1 entry into the cells, this drug was not 
approved for this purpose.121 In addition to poor oral bioavailability,122-123 AMD3100 is 
cardiotoxic.122, 124 The FDA approved AMD3100 for limited use in patients with multiple myeloma 
in order to mobilize and harvest stem cells.119, 125-126 
It was speculated that the toxicity and poor oral bioavailability of AMD3100 stemmed from 
the bicyclam rings. To verify this, new analogues were designed and synthesized in which the 
bicyclams rings were replaced. These studies led to the synthesis of a potent p-xylyl-enediamines 
derivate, WZ811 (Figure 9).127 There are several other categories of CXCR4 antagonists 
including: cyclic pentapeptide-based antagonists, indole based antagonists, and 
tetrahydroquinoline-based antagonists.92 Of these classes, several modulators are in clinical  
trials,92 where a majority of them are peptide based.128 Many of the p-xylyl-enediamine compounds 
have shown CXCR4 activity but very few have gone on to clinical trials primarily due to toxicity 
or bioavailability issues.92 Various substituents and side chains have been analyzed in the p-xylyl-
enediamine class of compounds and have been screened for CXCR4 activity. The cyclams and 
bicyclams are among the most studied in this group;127 however, there has not been robust 
structure-activity relationship (SAR) studies in which the central phenyl ring has been altered to 
another aromatic ring.  
 
2.2 Rationale for Design 
AMD3100 and other p-xylyl-enediamines are structurally specific drugs, drugs that 
interact at a specific site. Changes to the structure of a lead compound can affect the biological 
activity of such a type of drug.129  Using this information, it is possible to map out the relation 
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between structure of a compound and activity of a compound by making small changes to a lead 
compound—called Structure Activity Relationship (SAR)—and draw conclusions about the active 
site where the compound is interacting.  
 
Figure 8: Progression of AMD3100 from JM1498 
 
It was this process that lead to the development of AMD3100 from JM1498 (Figure 8). 
JM1657 was discovered as an HIV inhibitor through screening several commercially available 
cyclam rings.119 JM1657 was found to be an impurity from synthesizing JM1498 and was then 
characterized.119 A series of small modifications were made to the linker between the two cyclam 
rings and the lead out of the compound was a benzene ring, connected to the cyclam rings at the 1 
and 4 position by a methylene, JM2987 (also known as AMD3100).119  
AMD3100 was the first CXCR4 antagonist to become FDA approved;121 however, it was 
for one time use to treat multiple myeloma—not HIV. The compound was cardio-toxic.122, 124 
AMD3100 was still a good lead to branch off for more SAR studies to mitigate these negative 
effects. This gave birth to the class of CXCR4 antagonists called p-xylyl-enediamines. The central 
benzene ring was preserved, and at the 1 and 4 positions, different substituents were used to replace 
the cyclam rings.92, 127  The active compounds in this class often have benzene-based, pyridine-
based or pyrimidine-based side chains replacing one or more of the cyclam rings.92 Two 
forerunners out of this class of compound (Figure 9), were WZ811 (where the cyclam rings have 
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been replaced with a 2-aminopyridinyl group)130 and MSX122 (where the cyclam rings have been 
replaced with a 2-aminopyrimidinyl group).131   
Figure 9: Progression from AMD3100 to MSX122 
 
The p-xylyl-enediamine compounds which removed the cyclam rings have eliminated the 
toxicity issue due to metal chelation;130 however, only MSX-122 has shown promising oral 
bioavailability and has made it to clinical trials but it suspended for undisclosed reasons in 2008.92 
Many of the other analogues, including WZ811 are not orally bioavailable and have a short half-
life in the body.120   
In designing a new class of compounds using WZ811 and MSX122 as leads to make a 
more orally bioavailable analogue, the qualities that make a compound orally bioavailable must 
be examined. Lipinski’s rule of five132-134 states that compounds with two or more of the following 
traits are likely to be poorly orally bioavailable: molecular weights over 500 g/mol, more than five 
hydrogen bond donors, more than ten hydrogen bond acceptors and a log P value greater than 5. 
Naturally, there are exceptions to this rule and more detailed parameters have been outlined to 
account for the exceptions by Ghose et al. Ghose et al. suggests that a log P value between -0.4 
and 5.6 and a molecular weight between 180 g/mol and 500 g/mol increase drug-likeness.135 When 
examining WZ811 and MSX122 by each of these parameters, they fall well within the parameters 
of rules of five. Both leads have molecular weights above 180 g/mol and below 500 g/mol, 
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Hydrogen bond donors are defined as the sum of hydroxyl and amino groups.129 Both leads 
have two each and are again, well within Lipinski’s range. Hydrogen bond acceptors are defined 
as the sum nitrogen and oxygen atoms.129 WZ811 and MSX122 have four and six, respectively. 
The last parameter is a log P value between -0.4 and 5.6 as modified by Ghose et al.135 Log P is 
the partition coefficient which is a measure how lipophilic a molecule is and is calculated by 
talking the log of the solubility of the molecule in 1-octanol over the solubility of the compound 
in water.129 For WZ811 and MSX122, the calculated log P values, using Molinspiration, were 2.65 
and 1.65 respectively.136 
Since both compounds fall within the range of these rules, it is possible that the lower log 
P for MSX122 contributes to its oral bioavailability. In the structure of the p-xylyl-enediamines, 
the common motif is the central benzene ring. In previous studies, benzene ring has been altered 
to aliphatic rings130 and aliphatic chains137 and both resulted in a loss of activity; however, a 2,6-
pyridine analogue and a 3,5-pyridine analogue based on AMD3100 were synthesized. They were 
not as active as AMD3100, but they were still active.137 Pyridine and other heterocyclic aromatic 
rings such as pyrazine, furan, and thiophene have lower log P values than benzene as shown in the 
Table 1 below.138-141 
 
Ring Structure Log P 
Benzene 
 
2.13a 
Pyridine 
 
0.65a 
Pyrazine 
 
-0.26b 
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Furan 
 
1.34a 
Thiophene 
 
1.81a 
Table 1: Ring structures and their corresponding log P values. aValues from Exploring QSAR.138 
bValues from Human Metabolome Database.139-141 
 
Analogues that change the linker from benzene to other heterocyclic aromatic rings 
following the p-xylyl-enediamine motif may retain activity while lowering the log P value. It is 
these such analogues that were synthesized in this work (Figure 10). The potential of lowering the 
log P value combined with the frequent use of pyridines,142 thiophenes,143 and furans144 and 
pyrazines145 in medicine, set a precedence for this work. This work will focus particularly on anti-
metastatic activity and anti-inflammatory activity of these analogues since HIV-1 binds differently 
than CXCL12,146 and the analogues synthesized are generally too small to block HIV-1 as a co-
receptor.  
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Figure 10: Progression from AMD3100 to the compounds synthesized and analyzed in this 
work. The 2,5-thiophene series was synthesized by Francisco Garcia. 
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2.3 Results and Discussion 
2.3.1 Chemistry 
2.3.1.1 2,6-Pyridine analogues 
The 2,6-pyridine analogues (2a-x) were synthesized via a reductive amination reaction 
between 2,6-pyridinedicarbaldehyde (1) and a substituted amine. 
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Scheme 1: Synthesis of 2,6-pyridine analogues. 
 
2.3.1.2 2,5-Furan analogues 
The 2,5-furan analogues (4a-u) were synthesized via a reductive amination reaction 
between 2,5-furandicarbaldehyde (3) and a substituted amine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2: Synthesis of 2,5-furan analogues.  
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2.3.1.3 3,4-Thiophene analogues 
Synthesized by reducing the 3,4-thiophenedicarboxyllic acid (5) to an alcohol using 
diisobutylaluminum hydride. The resulting dialcohol (6) was quenched and isolated before it was 
oxidized over manganese dioxide to give the dicarbaldehyde product (7). 
 
 
Scheme 3: Synthesis of 3,4-thiophenedicarbaldehyde. 
 
The 3,4-thiophene analogues (8a-j) were synthesized via a reductive amination reaction 
between 3,4-thiophenedicarbaldehyde (7) and a substituted amine (Scheme 4). 
 
 
Scheme 4: Synthesis of 3,4-thiophene analogues. 
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In synthesizing the 3,4-thiophene analogues, the bis(amino) product is not the major 
product. In this reductive amination, when one of the aldehydes reacts with the amine, the same 
amine will undergo a second, intramolecular, reductive amination leading to compound 8” shown 
above in Scheme 4. This compound is favorable because of the formation of the five-membered 
ring. This percent yield of the desired analogue, compound 8, was increased by breaking up the 
reaction into a two-step process where the imine is isolated, and then reduced; however, the 
cyclized compound is still the major product. 
.  
2.3.1.4 2,5-Pyrazine analogues 
The 2,5-pyrazinedicarbaldehyde starting material was synthesized through a series of 
reactions starting from 2,5-dimethylpyrazine. These reactions are shown below in Scheme 5. The 
nitrogens on the pyrazine are oxidized under mCPBA. The resulting oxidized compound is 
refluxed in acetic anhydride to encourage a substitution of the anhydride followed by a 
rearrangement to the methyl group. The resulting compound (11) is then stirred in sodium 
hydroxide to yield the dialcohol product (12). This compound was then oxidized using manganese 
dioxide to yield the starting aldehyde.   
 
 
Scheme 5: Synthesis of 2,5-pyrazinedicarbaldehyde. 
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The 2,5-pyrazine analogues (14a-d) were synthesized via a reductive amination reaction 
between 2,5-prazinedicarbaldehyde (13) and a substituted amine (Scheme 6). 
 
Scheme 6: Synthesis of 2,5-pyrazine analogues. 
 
 
2.3.2 Biology 
All biological assays were completed by our collaborators at Emory University in Dr. 
Hyunsuk Shim’s laboratory at the Winship Cancer Institute. 
 
2.3.2.1 Binding Assay 
The derivatives were tested in a semi-quantitative binding affinity assay. It is important to 
emphasize that this assay is used as a preliminary screen for potential CXCR4 antagonists that will 
warrant further testing. The MDA-MB-231 breast cancer cells are incubated with the compounds 
at 1 nM, 10 nM, 100 nM and 1000 nM concentrations. Next, the cells are incubated with a 
biotinylated peptide, TN14003 (a known CXCR4 inhibitor), followed by streptavidin-rhodamine. 
The fluorescence of the cells is then measured to obtain effective concentration (EC) is obtained. 
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EC is the lowest concentration of the compound where there is a significant reduction in 
fluorescence observed compared to the positive control. All compounds synthesized were screened 
using this binding assay. Compounds that scored at 100 nM and below were then subjected to the 
Matrigel invasion assay. Figure 11 below shows examples of what the fluorescence looks like at 
different effective concentrations. 
 
Figure 11: Reduction of inflammation observed for selected derivatives. 2i had an EC of 10 nM. 
2c had an EC of 100 nM and 2r had an EC of 1000 nM. 
 
2.3.2.2 Matrigel Invasion Assay 
The Matrigel invasion assay is used as a functional assay to probe if the synthesized 
analogues can block CXCR4/CXCR12 mediated chemotaxis and invasion. This assay uses a 
special two chambered apparatus. MDA-MB-231 cells that have been incubated in 100 nM 
concentrations of the analogues are placed in the top chamber and CXCL12 is placed in the bottom 
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chamber as a chemoattractant. The partition between the two chambers is a Matrigel matrix that 
the MDA-MB-231 cells can pass through. The measurement gained in this assay is a percentage 
of inhibition of chemotaxis. When the assay is complete, the number of cells that migrated through 
the matrix is counted. The percent inhibition is the percentage of cells that were prevented from 
migrating compared to the negative control. The stronger the inhibitor, the fewer cells that pass 
through the membrane.  
Only the compounds that showed promise in the binding assay (EC ≤ 100 nm) were tested 
in the Matrigel invasion assay. The two compounds used as benchmarks were AMD3100 and 
WZ811.  An invasion inhibition above 35% was favorable. The results for this assay have been 
consolidated with the results from the binding assay for each class of compound in Tables 2 
through 6, where AMD3100 and WZ811 were used as benchmarks for comparison. 
 
 
Compd R Group EC (nM) Invasiona Compd R Group 
EC 
(nM) 
Invasiona 
2a aniline 100 <1% 2m 4-Cl aniline 100 21% 
2b 2-Me aniline >1000 -- 2n 2-OMe aniline 1000 <1% 
2c 3-Me aniline 100 60% 2o 3-OMe aniline 100 37% 
2d 4-Me aniline 1000 -- 2p 4-OMe aniline 100 5% 
2e 2-Et aniline 1 59% 2q 2-CF3 aniline >1000 -- 
2f 3-Et aniline 1000 -- 2r 3-CF3 aniline 1000 15% 
2g 4-Et aniline 1 64% 2s 4-CF3 aniline 1 52% 
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2h 2-F aniline 1000 -- 2t 4-SMe aniline >1000 -- 
2i 3-F aniline 10 50% 2u 3-NO2 aniline >1000 -- 
2j 4-F aniline 
100 
 5% 2v 4-NO2 aniline >1000 -- 
2k 2-Cl aniline >1000 -- 2w Morpholine 10 63% 
2l 3-Cl aniline 100 34% 2x Pyrrolidine 1 58% 
AMD3100131, 
147 --- 1000 62%     
WZ811127 --- 10 90%     
Table 2: Binding and invasion assay results for pyridine analogues synthesized. aThe invasion 
assay concentration used for all compounds tested was 100nM. 
 
In the pyridine analogues (Table 2), eight performed well in both assays. Six of these eight 
analogues contained aniline-based side chains and the other two were the morpholino analogue 
(2w), and the pyrrolidinyl analougue (2x) which had binding assay resutls of 10 nM and 1 nM 
respectively, and invasion assay inhibition of 63% and 58% respectively. Out of these compounds, 
it seems that analogues with electron withdrawing groups as side chains are not favoured; the nitro 
comounds did not have activity and the chloro compounds did not have favourable activity. The 
exception is in the trifluoromethyl family, where none of the analogues were active except for the 
4-CF3 anilino analogue (2s); where the binding assay concentration was 1 nM and the invasion 
inhibition was 52%. Perhaps the CF3 groups in the para position has a favourable interaction in the 
pocket that wasn’t favourable for the 4-Me aniline (2d)—as they would take up nearly the same 
amount of space. In silico analyses would be required to gain insight into this.  
The 3-Fluoro aniline analogue (2i) showed favourable activity with a binding of 10 nM 
and an invasion inhhibition of 50%. Halogens are weakly electron withdrawing and have lone pairs 
that may be used for donation. This could be another reason why the chloro anilino analogues had 
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some activity but none favourable. This could also be why this fluoro analogue had favourable 
activity. Of the methyl analogues, only the 3-Methyl aniline (2c) had faourable activity with an 
effective concentration of 100 nM and an invasion inhibition of 60%. The 2-Ethyl (2e) and 4-Ethyl 
(2g) aniline analogues showed promising sctivity with effective concentrations of 1 nM for both 
and invasion assay inhibitions of 59% and 64% respectively. Lastly, the 3-Methoxy aniline (2o) 
showed favourable activity with an effective concentration of 100 nM and an invasion inhibition 
of 37%. It is interesting that this analogue had some activity were the 3-Ethyl (2f) did not. It could 
be possible that the lone pairs on the oxygen are able to interact with residues or solvent better in 
the active site compared to the 3-Ethyl aniline analogue. Where the ortho and para position ethyl 
groups have hydrophobic interactions at those positions. 
 
   
Compd R Group 
EC 
(nM) 
Invasiona Compd R Group 
EC 
(nM) 
Invasiona 
4a Aniline >1000 -- 4l 3-Cl aniline >1000 -- 
4b 2-Me aniline >1000 -- 4m 4-Cl aniline 10 48% 
4c 3-Me aniline >1000 -- 4n 2-OMe aniline 100 5% 
4d 4-Me aniline 100 75% 4o 3-OMe aniline >1000 -- 
4e 2-Et aniline 1000 -- 4p 4-OMe aniline >1000 -- 
4f 3-Et aniline >1000 -- 4q 2-CF3 aniline 100 24% 
4g 4-Et aniline >1000 -- 4r 3-CF3 aniline >1000 -- 
4h 2-F aniline 10 71% 4s 4-CF3 aniline >1000 -- 
4i 3-F aniline >1000 -- 4t 4-SMe aniline >1000 -- 
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4j 4-F aniline 100 53% 4u 1-methylpiperazine 10 82% 
4k 2-Cl aniline >1000 --     
AMD3100131, 147 --- 1000 62%     
WZ811127 --- 10 90%     
Table 3: Binding and invasion assay results for furan analogues synthesized. aThe invasion assay 
concentration used for all compounds tested was 100nM. 
 
Of the 2,5-furan analogues synthesized (Table 3), five analogues performed well. First was 
the 4-Methyl aniline (4d), which had an effective concentration of 100 nM and an invasion 
inhibition of 75%. The 2-Fluoro (4h) and 4-Fluro (4j) aniline derivatives had effective 
concentrations of 10 and 100 nM respectively and invasion inhibition of 71% and 53% 
respectively. The 4-Chloro aniline analogue (4m) had an effective concentration of 10 nM and 
invasion inhibition of 48%. The 1-methylpiperazine analogue (4u) had an effective concentration 
of 10 nM and inhibited 82% of metastatic cells from invading—the highest percentage of any of 
the other compounds synthesized in this work. 
It is interesting to note for the 2,5-furanoaniline-based compounds the only compounds 
that showed activity were compounds with ortho and para substitutions. Overall, it seems that 
weakly electron donating groups like methyl and weakly electron withdrawing groups like the 
fluorine and chlorine had the most activity. The 2-CF3 analogue (4q) had some activity with an 
effective concentration of 10 nM and an invasion inhibition of 24%; however, it is not enough for 
it to pass on to the paw edema test. All other 2,5-furan based compounds had no significant activity. 
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Compd R Group EC (nM) Invasiona Compd R Group 
EC 
(nM) 
Invasiona 
8a Aniline 10 72% 8f 4-F aniline >1000 -- 
8b 3-Me aniline >1000 -- 8g 3-Cl aniline >1000 -- 
8c 4-Me aniline >1000 9% 8h 4-Cl aniline >1000 -- 
8d 4-Et aniline >1000 -- 8i 3-CF3 aniline >1000 -- 
8e 3-F aniline >1000 -- 8j 4-CF3 aniline >1000 -- 
AMD3100131, 
147 --- 1000 62%     
WZ811127 --- 10 90%     
Table 4: Binding and invasion assay results for the 3,4-Thiophene analogues synthesized. aThe 
invasion assay concentration used for all compounds tested was 100nM. 
 
Of the 3,4-thiophene analogues (Table 4), only the anilino analogue (8a) showed 
favourable activity with an effective concentration of 10 nM and an invasion inhibition of 72%. 
All other compounds had an effective concentration over 1000 nM and did not show significant 
activity. 
 
   
 
Compd R Group EC (nM) Invasiona Compd R Group 
EC 
(nM) 
Invasiona 
14a aniline >1000 -- 14c 4-Et aniline >1000 -- 
14b 3-Me aniline >1000 -- 14d 4-F aniline 10 76% 
AMD3100131, 
147 --- 1000 62%     
WZ811127 --- 10 90%     
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Table 5: Binding and invasion assay results for pyrazine analogues synthesized. aThe invasion 
assay concentration used for all compounds tested was 100nM. 
 
Of the 2,5-pyrazine analogues (Table 5), only the 4-Fluoro anilino analogue (14d) 
exhibited favorable activity with an effective concentration of 10 nM and an invasion inhibition of 
76%. Since only four analogues of this series have been synthesized, there is not enough data to 
speculate trends. 
 
 
 
Compd R Group EC (nM) Invasiona Compd R Group 
EC 
(nM) 
Invasiona 
15a aniline 1 68% 15n 2-OMe aniline 10 52% 
15b 2-Me aniline 10 61% 15o 3-OMe aniline 1000 -- 
15c 3-Me aniline >1000 -- 15p 4-OMe aniline 10 84% 
15d 4-Me aniline 100 49% 15q 2-CF3 aniline >1000 -- 
15e 2-Et aniline 1000 -- 15r 3-CF3 aniline 100 77% 
15f 3-Et aniline >1000 -- 15s 4-CF3 aniline >1000 -- 
15g 4-Et aniline >1000 -- 15t Morpholine >1000 -- 
15h 2-F aniline 1000 -- 15u Thiomorpholine 1 88% 
15i 3-F aniline >1000 -- 15v Piperidine 1000 -- 
15j 4-F aniline >1000 -- 15w 4-CF3 Benzylamine 1 97% 
15k 2-Cl aniline 10 93% 15x 3-F Benzylamine >1000 -- 
15l 3-Cl aniline 100 51% 15y 4-Cl Benzylamine >1000 -- 
38 
15m 4-Cl aniline 1 22%     
AMD3100131, 
147 --- 1000 62%     
WZ811127 --- 10 90%     
Table 6: 2,5-Thiophene analogues synthesized by Francisco Garcia148 which will be analyzed in 
the discussion section of this work as well as in silico. 
 
A detailed summary of the 2,5-thiophene compound’s synthesis and trends can be found 
in Francisco Garcia’s thesis;148 however, the most direct and straightforward comparison to be 
made is between the 2,5-thiophene analogues and the 2-5-furan analogues. Unlike the furan 
aniline-based compounds which only displayed activity for weakly electron donating and weakly 
electron withdrawing groups, the thiophene derivatives seem to show more activity across the 
board. None of the thiophene fluoroaniline analogues had activity, where the furan derivatives had 
activity with the ortho and para fluoroaniline sidechains. The thiophene chloroaniline derivatives 
also had activity where only one of the furan-based chlorine substituents had activity. It is possible 
that the electronics of the 2,5-thiophene are such that those derivatives are able to interact better 
with the residues in the active site compared to the 2,5-furan. It’s also possible that the size 
difference between the 2,5-thiophene and the 2,5-furan contribute to the difference between the 
two.  
Between the 3,4-thiophene and the 2,5-thiophene, it is clear that the 3,4 positioning leads 
to loss of activity. It’s possible that the 2,5-thiophene compounds are able to fit better into the 
active site because of the geometry of the analogues. This would need to be explored further in 
silico. 
Overall, there are no strong motifs for substituents across the different core molecules. 
Both the pyridine and 2,5-thiophene analogues had a variety of substituents that had activity in the 
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binding and Matrigel invasion assays with no clear pattern. It is worth noting that even though the 
2,6-pyridine morpholino analogue (2w) had activity, the 2,5-thiophene morpholino analogue (15t) 
did not. Instead, the 2,5-thiophene thiomorpholino derivative (15u) had activity. Compound 4u, 
which also had a heterocyclic substituent, 1-methylpiperazine, follows in this trend and had 
significant activity. Further probing would need to be done in synthesizing more derivatives as 
well as in silico analysis to paint a bigger picture and complete this library. 
 
2.3.2.3 In vivo carrageenan suppression 
The mouse paw edema model is used as a proof-of-concept test.127, 131 If these analogues 
are able to disrupt the CXCR4-CXCL12 interaction, then it also has an effect on inflammation. If 
inflammation were to be induced in the presence of these compounds, a reduction in said 
inflammation would be observed for potent CXCR4 antagonists. All compounds that performed 
well in both the binding assay and Matrigel invasion assay were submitted for the paw edema test. 
This test is also a way to gain insight into the toxicity of our compounds. None of the mice that 
were given the synthesized analogues died during this test. 
In this test, the hind paws of mice are inflamed using carrageenan, and one paw is treated 
with a solution of the analogue (10 mg of analogue per kg), and the other is treated with a saline 
solution. Both the saline solution and analogue solution are delivered via injection into the paw. 
The paws are then measured at the end of the test using calipers to determine the percent reduction 
in swelling. Compounds that score 100 nM or below in the binding assay and above a 35% in the 
invasion assay were considered hit compounds and were submitted for further analysis in the paw 
edema test. Of the compounds synthesized, fifteen qualified for the mouse paw edema test (shown 
in Table 7). 
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Compd R Group EC (nM) Invasiona Carageenanb,c 
2c 3-Me aniline 100 60% 20% 
2e 2-Et aniline 1 59% 18% 
2g 4-Et aniline 1 64% 42% 
2i 3-F aniline 10 50% 20% 
2o 3-OMe aniline 100 37% 20% 
2s 4-CF3 aniline 1 52% 20% 
2w Morpholine 10 63% 39% 
2x Pyrrolidine 1 58% -- 
4d 4-Me aniline 100 75% 15% 
4h 2-F aniline 10 71% -- 
4j 4-F aniline 100 53% 31% 
4m 4-Cl aniline 10 48% 17% 
4u 1-Methylpiperazine 10 82% -- 
8a Aniline 10 72% -- 
14d 4-F aniline 10 76% 32% 
AMD3100131, 147  1000 62% -- 
WZ811127  10 90% 40% 
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Table 7: Assay and test results for hit compounds. aThe concentration used in the invasion assay 
was 100 nM. bMice were dosed used 10 mg of compound for every kg the mouse weighed in this 
assay. cCompounds with a dash in the carrageenan studies have not yet been submitted. 
 
WZ811 is used as the benchmark in this assay, where paw edema test, WZ811 reduced 
inflammation by 40% compared to the control. Two compounds, the 4-Ethyl pyridine (2g) and the 
morpholino pyridinee (2w) reduced inflammation on par with WZ811 at 42% and 39% 
respectively. The para fluoro furan (4j) ands pyrazine derivative (14d) both follow close behind 
with inflammation reduction of 31% and 32% respectively. 
The tissue slice shown in Figure 12 was taken from a mouse paw that was treated with the 
3-fluoro pyridine-based analogue 2i. Even though 2i did not perform the best out of the compounds 
selected for the carrageenan study (20%), these tissue slices show that even though the reduction 
in swelling was smaller, these compounds are still mitigating the inflammatory response in the 
inflamed tissue—where the inflamed dermal papilla is returning to its normal curved and spiked 
shape compared to the inflamed shape where it becomes flat and smooth. 
In light of this, it is worth noting that several compounds reduced swelling in the range of 
2i. The 3-methyl pyridine derivative (2c), reduced swelling by 20%. The 3-methoxy pyridine (2o) 
reduced inflammation by 20%. The para trifluoromethyl pyridine analogue (2s) reduced swelling 
by 20%. Since tissue slices were not taken for each of these compounds, it could be a stretch to 
assume that all of them are showing this activity in the tissue; however, it is promising to know 
that some compounds that don’t reduce swelling as dramatically are restoring normal tissue shape. 
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Figure 12: Histological assay of compound 2i. Paw tissue sections were stained with H&E. The 
whole tissue slices were scanned/digitized by NanoZoomer 2.0 HT. Software NDP.view 2 was 
used to zoom in. 
 
The other remaining compounds, did not have a reduction in swelling above 20% compared 
to the control, but some swelling reduction was observed. There is no clear relation between low 
effective concentration, high invasion inhibition and inflammation reduction. Several compounds 
that scored well in the preliminary assays showed lower edema reduction. 2e and 4d are prime 
examples of this, it could be possible that these compounds do not completely block CXCR4 and 
CXCL12 is still able to interact with the receptor to trigger inflammation. Bioavailability may be 
an issue as these analogues might not stay in circulation long enough to mitigate inflammation 
before they are flushed out by the body. Further studies would be needed to determine the 
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pharmacokinetic properties and discern if this is an issue. There are remaining compounds that 
need to be submitted for paw edema analysis; however, the data so far lays a good foundation for 
analysis and future plans for this work. 
 
2.4 Summary of Analogues Designed and Synthesized 
The compounds shown in Table 8 below show the hit compounds from this work and 
Francisco Garcia’s work. Very few of the 2,5-thiophene compounds synthesized have been 
submitted for the paw edema test, so it is difficult to make a complete analysis or comparison in 
that regard; however out of all the five core molecules that have been synthesized, the 2,5-
thiophenes have had the most active compounds with the best invasion assay inhibitions, where 
compounds 15k, 15p, 15u and 15w all inhibited upwards of 80% of had invasion assay results that 
high. In the pyridine analogues, the 3-methyl (2c), 4-ethyl (2g), and the morpholino (2w) analogues 
all had invasion assay results above 60% inhibition. The 2,5-furan (4d, 4h and 4u) and the 3,4-
thiophene series (8a) both had derivatives with invasion assay inhibition over 70%. 
Complete inhibition of invasion—and by extension, the CXCR4/CXCL12 interaction is 
undesirable as activity is necessary for normal cell function; however, in probing what about these 
2,5-thiophene analogues enables it to block this interaction and prevent metastasis, future 
analogues could be used as a lead to further tweak to be a suitable antagonist. 
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Compd R Group EC (nM) Invasiona Carageenanb,c 
2c 3-Me aniline 100 60% 20% 
2e 2-Et aniline 1 59% 18% 
2g 4-Et aniline 1 64% 42% 
2i 3-F aniline 10 50% 20% 
2o 3-OMe aniline 100 37% 20% 
2s 4-CF3 aniline 1 52% 20% 
2w Morpholine 10 63% 39% 
2x Pyrrolidine 1 58% -- 
4d 4-Me aniline 100 75% 15% 
4h 2-F aniline 10 71% -- 
4j 4-F aniline 100 53% 31% 
4m 4-Cl aniline 10 48% 17% 
4u 1-Methylpiperazine 10 82% -- 
8a Aniline 10 72% -- 
14d 4-F aniline 10 76% 32% 
15ad Aniline 1 68% 30% 
15bd 2-Me aniline 10 61% -- 
15dd 4-Me aniline 100 49% -- 
15kd 2-Cl aniline 10 93% >5% 
15ld 3-Cl aniline 100 51% -- 
15nd 2-OMe aniline 10 52% -- 
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15pd 4-OMe aniline 10 84% -- 
15rd 3-CF3 aniline 100 77% -- 
15ud Thiomorpholine 1 88% -- 
15wd 4-CF3 Benzylamine 1 97% 23% 
AMD3100131, 147  1000 62% -- 
WZ811127  10 90% 40% 
Table 8: Assay and test results for hit compounds. aThe concentration used in the invasion assay 
was 100nM. bMice were dosed used 10mg of compound for every kg the mouse weighed. 
cCompounds with a dash in the carrageenan studies have not yet been tested. dCompounds 
synthesized by Francisco Garcia148 which will be analyzed in the discussion section of this work 
as well as in silico. 
 
Even though the 2,5-thiophene series seem to perform well in the binding and invasion 
assay, the preliminary data from the paw edema test shows that they are not reducing inflammation 
in vivo as well as they prevented metastasis in vitro compared to the pyridine or furan-based 
analogues. Where 15w and 15k, had invasion scores of 93% and 97% respectively, they only 
reduced inflammation by 30% and 23% respectively. Compared to 2g which had invasion assay 
inhibition of 64% and an inflammation reduction of 42%, it seems that performance in the invasion 
assay is not a good predictor for the success of the paw edema test.  
As mentioned in the rationale for design, desirable pharmacokinetic properties tend to 
increase as the partition coefficient of a potential drug is lowered. Both the pyridine and furan 
rings have a lower log P than thiophene. If the 2,5-thiophene analogue’s log P is not low enough, 
it may be flushed out of the body too quickly to effectively reduce swelling in this assay. If this 
trend continues as more and more 2,5-thiophene analogues are submitted for the paw edema test, 
using substituents that lower the overall partition coefficient may yield better results. 
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Similarly, perhaps the pyridine compounds were able to do relatively well in the paw 
edema test because of the lower partition coefficient. Even though they did not inhibit invasion of 
more than 60% of the metastatic cells compared to the control, perhaps their results in the paw 
edema assay are consistently active because of their drug-likeness due to the lowered log P. This 
would need to be further evaluated in pharmacokinetic tests. 
The 3,4-thiophene analogues overall were not active, with only the aniline derivative (8a) 
showing activity. This seems to suggest, that the geometry of the 2,5 positioned five membered 
rings may be favorable. This could be analyzed further by synthesizing 3,4-furan-based analogues 
for comparison. Since the log P of pyrazine is lower than all of the other heterocyclic aromatic 
rings, the pyrazine, further analogue synthesis should be conducted in order to complete this 
section of the library; however, the activity of the 4-fluoro pyrazine (14d) is a promising first look. 
Overall, analogues 2g, 2w, 4j,14d, and 15a are the five best compounds synthesized and 
analyzed so far with favorable effective concentrations, invasion inhibition properties and with 
inflammation reduction above 30% compared to the control.  
 
 
   
47 
3     DOCKING ANALYSIS 
 
3.1 Schrӧdinger Small Molecule Suite 
To gain insight as to how these analogues are interacting with the active site, in silico 
methods used. In addition to the analogues synthesized in this work, analysis for 2,5-thiophene 
(15a-y) derivatives synthesized by Francisco Garcia148 are also provided in this work. Preliminary 
docking analysis of several of the 2,6-pyridine compounds were conducted in a previous work by 
Dr. Davita Camp. Previous work has identified several key residues that can block the CXCR4-
CXCL12 interaction. Some of these residues include ASP97, GLU288, ASP187, PHE87, ASP171, 
and PHE292, where the first three are required for signaling pathways triggered by CXCL12.57-58 
Docking scores and key residue interactions for hit compounds are shown in Table 9. 
 
 
Compd R Group EC (nM) 
Docking Score 
(kcal/mol) 
Key Residue 
Interactions 
2c 3-Me aniline 100 -7.314 
GLU288, TRP94, 
CYS186 
2e 2-Et aniline 1 -5.944 HID113 
2g 4-Et aniline 1 -5.716 TRP94, GLU288 
2i 3-F aniline 10 -6.822 ASP97a 
2o 3-OMe aniline 100 -6.187 TRP94, ASP97a 
2s 4-CF3 aniline 1 -6.026 
TRP94,a ASP97, 
HID113, CYS186 
2w Morpholine 10 -7.173 
ASP97,a HID113, 
TYR116 
2x Pyrrolidine 1 -6.400 
ASP97, TYR116, 
CYS186 
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4d 4-Me aniline 100 -4.809 
HID113, ARG188, 
GLN200 
4h 2-F aniline 10 -4.869 TRP94 
4j 4-F aniline 100 -5.524 
TRP94, CYS186, 
ARG188, GLU288 
4m 4-Cl aniline 10 -5.300 HID113, CYS186 
4u 1-Methylpiperazine 10 -6.373 
TRP94, TYR116, 
GLU288 
8a Aniline 10 -3.437 
ASP97, HID113, 
ARG188 
14d 4-F aniline 10 -4.600 
ASP97, HID113, 
ARG188 
15ab Aniline 1 -4.773 ASP97 
15bb 2-Me aniline 10 -4.354 TRP94, HID113 
15db 4-Me aniline 100 -4.506 TRP94, CYS186 
15kb 2-Cl aniline 10 -4.840 TRP94, ASP97 
15lb 3-Cl aniline 100 -5.975 ASP97 
15nb 2-OMe aniline 10 -5.409 ASP97 
15pb 4-OMe aniline 10 -4.479 
GLU32, ASP97, 
ARG183 
15rb 3-CF3 aniline 100 -5.944 TRP94, ASP97 
15ub Thiomorpholine 1 -3.782 TRP94, GLU288a 
Table 9: In silico results for hit compounds suing the Schrӧdinger Small Molecule Suite. aThe 
compound has two or more interactions with this residue. 
 
Out of all the compounds docked, the hit pyridine compounds had the lowest docking 
scores and out of the hit compounds the pyridine-based compounds had the best scores. The Ligand 
Preparation wizard in the Schrödinger program created two different ionized states for each of the 
pyridine analogues. The first, where the central ring was deprotonated, and a second where the 
nitrogen in the central pyridine was protonated (Figure 13). The protonated pyridine compounds 
had lower docking scores compared to the deprotonated version.  
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Figure 13: Compound 2i is shown here with the central pyridine protonated. 
 
Previous studies suggest that small molecules with a positively charged center can interact 
with better the acid residues in the active site.59 None of the other heterocyclic cores had an 
ionization where the center was protonated; however, certain substituents lead to protonation of 
the connecting amine. These substituents—morpholine, thiomorpholine and pyrrolidine have a 
generated ionization (Figure 14) where both amines are protonated creating a positive charge in 
the active site. These compounds also had a low docking score. 
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Figure 14: Protonated 1-methyl piperazine substituent in compound 4u. Pyrrolidine, morpholine 
and thiomorpholine substituents also had lower docking scores when protonated. 
 
Most of the active compounds docked have key residue interactions with ASP97, or 
GLU288—two of the three residues mentioned earlier that are necessary for signaling. CYS186, 
TRP94, and TYR116, when docked are programmed to freely rotate to allow the ligands to interact 
via hydrogen bonding, pi-pi interactions or pi-cation interactions. Compound 2o, shown in Figure 
15, displays pi-pi interactions with aromatic residues like TRP94, TYR116 and HID113.  
It is worth noting that several ligands which were not active in the binding and Matrigel 
assays were docked with low scores. One such example is 2h, shown in Figure 16. This compound 
has a docking score of -6.237 kcal/mol and has key residue interactions with TRP94, ASP97, and 
HID113. 2h was not active in any of the assays, with an effective concentration of 1000 nM. This 
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was the same, for other inactive compounds with a charged ionization state, including charged 
substituents like morpholine.  
 
Figure 15: Compound 2o is shown with pi-pi interactions with TRP94. 
 
 
Figure 16: Compound 2h had a low docking score and key residue interactions with TRP 94, 
ASP97, and HID113 in silico; however, in vivo failed to show activity. 
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Similarly, there were several compounds that had low effective concentrations and high 
invasion inhibition in vitro, but obtained a low docking score in silico. Compound 15u (shown in 
Figure 17) had an effective concentration of 1 nM and inhibited invasion of metastatic cells by 
88%. In silico results yielded a docking score of -3.782 kcal/mol even though it had a key residue 
interactions with GLU288. Overall, compared to the activity displayed in the assays, the 2,5-
thiophene analogues received higher docking scores compared to their in vitro activity. 
 
Figure 17: Compound 15u received a high docking score of -3.782 kcal/mol, contrary to 
promising scores the in vitro results in the binding and Matrigel invasion assays. 
 
These discrepancies show that the docking model is not perfect; however, there are a few 
themes that can be taken away and used to direct future compounds synthesized. Positive charged 
ligands are favoured in the active site. All pyridine-based and most furan-based analogues with a 
positive charge scored below -5.000 kcal/mol. Synthesis of these analogues with non-aromatic 
cyclical amines and heterocyclic as substituents that can be protonated as secondary amines could 
yield active compounds. 
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Additionally, as some analogues with aromaticity are able to have pi-pi interactions with 
nearby residues, the use of substituted benzylamines, which have an extra sp3 hybridized carbon 
linking the substituent to the core molecule, instead of substituted anilines may give more 
flexibility to the analogue to fit better inside the pocket to make those pi-pi interactions. 
 
3.2 AutoDock Vina 
Due to the ambiguity of the results of the docking analysis using the Schrӧdinger software, 
the docking analysis was partially repeated using AutoDock Vina149 on a select subset of the 2,6-
pyridine analogues to determine if the resulting data in these programs yield trends. Ten pyridine 
compounds were selected; six had activity in the binding and invasion assays, the other four did 
not. The docking scores are displayed below in Table 10. The key residue interactions are not 
listed because the AutoDock Vina program does not have an interaction wizard. 
 
Compd R Group EC (nM) Invasion Assay 
Docking Score 
(kcal/mol) 
2a Aniline 100 <1% -6.8 
2c 3-Me aniline 100 60% -7.3 
2e 2-Et aniline 1 59% -6.7 
2f 3-Et aniline 1000 -- -6.6 
2g 4-Et aniline 1 64% -7.1 
2h 2-F aniline 1000 -- -7.2 
2i 3-F aniline 100 50% -7.0 
2q 2-CF3 aniline >1000 -- -6.3 
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2w Morpholine 1 63% -5.5 
2x Pyrrolidine 1 58% -5.3 
Table 10: In silico results for select compounds using AutoDock Vina.  
 
 
Figure 18: The docked pyridine compounds in AutoDock Vina. All compounds are located away 
from the key residues. The CXCR4 monomer is shown here in ribbon form; however, the key 
residues are highlighted as stick representations. 
 
The docking in this program has no correlation between the assay results compared to in 
silico results. The morpholine and pyrrolidine analogues scored the highest; however, all the 
other analogues consistently scored between -6.3 and -7.3. The analogues were then visualized in 
AutoDock. Figure 18 shows the compounds in relation to the key residues and active site. The 
docked analogues are neither interacting with the key residues nor located within the active site. 
Figure 19 shows the analogues in relation to the docking gridbox.  
 
55 
 
Figure 19: The docked pyridine compounds shown in AutoDock in the docking gridbox. All of 
the docked compounds are centered away from the key residues towards the top of the gridbox. 
The CXCR4 monomer is shown here in ribbon form; however, the key residues are highlighted 
as stick representations. 
 
In response to the lack of trends in the first set of in silico results, the same selected 
pyridine analogues were docked using a biased gridbox. The gridbox was reduced in size and 
was re-centered on the active site of the CXCR4 monomer. Docking with a biased gridbox is 
investigative in nature as it may help force compounds into a favorable position in the active site 
that was not seen in the first gridbox was larger at the same runtime; however, the results from 
this set of docking analyses cannot replace the original results from the non-biased docking 
analysis. The results of the biased docking analysis can be found in Table 11, below. 
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Compd R Group EC (nM) Invasion Assay 
Docking Score 
(kcal/mol) 
2a Aniline 100 <1% -6.8 
2c 3-Me aniline 100 60% -3.6 
2e 2-Et aniline 1 59% -1.7 
2f 3-Et aniline 1000 -- -3.1 
2g 4-Et aniline 1 64% -1.8 
2h 2-F aniline 1000 -- -5.1 
2i 3-F aniline 100 50% -3.8 
2q 2-CF3 aniline >1000 -- -1.9 
2w Morpholine 1 63% -4.3 
2x Pyrrolidine 1 58% -4.4 
Table 11: In silico results for selected compounds using a biased gridbox in AutoDock Vina.  
 
The docking scores in the biased gridbox are markedly higher than in the non-biased 
gridbox with docking scores ranging from -1.7 to -6.8. Unfortunately the broadness in the range 
has not lead to correlation between active compounds and their assay scores. Hit compounds such 
as 2e, 2g, and 2w scored -1.7, -1.8 and -4.3 respectively, where inactive compounds such as 2f, 
2h, and 2q scored -3.1, -5.1 and -1.9 respectively. The visualization shown in Figure 20 and 
Figure 21 show the biased docked compounds and the biased gridbox. Like the unbiased gridbox 
first used, the analogues are as far away from the active site as they can be and are clustered in the 
top edge of the gridbox. 
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Figure 20: The docked pyridine compounds in AutoDock Vina using a biased gridbox. All 
compounds are located away from the key residues. The CXCR4 monomer is shown here in 
ribbon form; however, the key residues are highlighted as stick representations. 
 
 
 
Figure 21: The docked pyridine compounds shown in AutoDock in the biased gridbox. All of 
the docked analogues are centered away from the key residues towards the top of the gridbox. 
The CXCR4 monomer is shown here in ribbon form; however, the key residues are highlighted 
as stick representations. 
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The docking completed using AutoDock Vina has not yielded any additional information 
highlighting how these heterocyclic analogues are interacting with the active site of CXCR4 using 
the parameters outlined in this work Further analysis using another program or perhaps more 
exhaustiveness may give more information and insight. 
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4     CONCLUSIONS AND FUTURE OUTLOOK 
 
In this work, a small library of heterocyclic-based modulators for CXCR4 mimicking p-
xylyl-enediamines have been synthesized and analyzed in binding assays, Matrigrel invasion 
assays and an in vivo paw edema test. Overall, the 2,6-pyridine-based compounds and the 2,5-
thiophene based compounds had the best results in the assays overall; however, more 2,5-thiophen 
compounds need to be submitted for the paw edema test. The 3,4-thiophene analogues were largely 
inactive, possibly due to the geometry. The 2,5-furan analogues had several with activity; however, 
compared to the 2,5-thiophene compounds, they exhibit less activity. 
There are several ways to extend this project going into the future. The 2,5-pyraizne library 
needs to be completed and analyzed. For the 2,6-pyridine and 2,5-furan compounds, extending the 
sidechains by using benzylamines instead of anilines may boost activity as well, potentially 
enabling analogues to have pi-pi interactions with nearby residues and granting them more 
flexibility in the binding pocket. In addition to benzylamine substituents, more cyclic non-aromatic 
analogues need to be synthesized. In silico analysis suggests that these substituents are likely to be 
positively charged in physiological conditions and will interact with acidic key residues. The 
success of the pyrrolidine, morpholine, thiomorpholine and 1-methylpiperazine compounds set a 
precedence to further investigate this trend. 
In order to verify if the 3,4-thiophene was largely inactive because of the 3,4 positioning 
of the side chains, synthesis of 3,4-furan based derivatives can provide insight into if this is true. 
There are a few other core molecules that would contribute to this library as the 2,6-pyridine and 
2,5-pyrazine analogues have shown activity. Modeled after the 2,6-pyridine analogues, synthesis 
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of 2,6-pyrazine analogues could possibly increase activity as pyrazine has a lower log P than 
pyridine. It would also provide more information as to if the analogues are able to bind better in 
the pocket with another nitrogen in the heterocyclic ring can increase activity as in silico analysis 
suggests that the pyridine analogues are protonated in the active site and are able to bind differently 
be because of the positioning of the cation on the ring instead of on the amine. In silico results did 
not suggest protonation for the 2,5-pyrazine cores; however, 2,6-pyrazine should still be explored. 
In the same vein, synthesizing 2,5-pyrdine analogues that match the 2,5-pyrazine would be a useful 
addition to the library. 
For existing core molecules like the 2,5-thiophene and the 2,6-pyridine, using other amines 
that have shown to have exception activity in the p-xylyl-enediamine series such as the 2-
aminopyridine and 2-aminopyrimidine and halogen substituted 2-aminopyridine and 2-
aminopyrimidines. Design and synthesis of asymmetrical analogues of these core molecules could 
help increase activity by designing a small molecule that can fit better into the active site.  
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5     EXPERIMENTAL 
 
5.1 Biology 
All biological assays were completed by our collaborators at Emory University in Dr. 
Hyunsuk Shim’s laboratory at the Winship Cancer Institute. 
 
5.1.1 Primary Binding Affinity Screening 
The binding affinity assay is a competitive assay where approximately twenty thousand 
MDA-MB-231 breast cancer cells are incubated an 8-well slide chamber for two days in 300 μL 
of medium. The compounds were also incubated in separate wells at several concentrations (1, 10, 
100, 1000 nM) for ten minutes at room temperature. The cells were then fixed in a chilled solution 
of 4% paraformaldehyde. After the cells were rehydrated in phosphate-buffered saline (PBS), the 
slides were prepared by incubating them with 0.05 μg/mL biotinylated TN14003 for thirty minutes 
at room temperature.  These slides were washed three times with the PBS solution and were then 
incubated for thirty minutes at room temperature in streptavidin-rhodamine (1:150 dilution; 
Jackson ImmunoResearch Laboratories, West Grove, PA). The slides were washed again with the 
PBS solution and were mounted in an antifade mounting solution (Molecular Probes, Eugene, OR). 
A Nikon Eclipse E800 microscope was used to analyze the samples.127, 150 
 
5.1.2 Matrigel Invasion Assay 
This assay was performed using a Matrigel invasion chamber (Corning Biocoat; Bedford, 
MA). In the bottom chamber, a solution of CXCL12 (200ng/mL; R&D Systems, Minneapolis, 
MN) was added to the apparatus. 100nm of the selected compounds (or AMD3100 as a control) 
62 
were added to the MDA-MB-231. The cells were then placed in the top chamber. The apparatus 
was then incubated in a humidified incubator for 22 hours. The remaining cells in the top chamber 
were removed using a cotton swab and the invading cells in the bottom chamber were stained 
hematoxylin and eosin (H&E) and fixed with methanol. The rate of invasion was calculated by 
counting the invading (stained) cells.127, 150 
 
5.1.3 Paw Inflammation Suppression Test 
In this test, C57BL/6J does (Jackson Laboratories) are subcutaneously injected with λ-
carrageenan (50 μL in 1% w/v in saline) in the right hind paw to trigger inflammation; the other 
hind paw is used as the non-inflammation control. The selected analogues were prepared in 10% 
DMSO and 90% of 45% (2-hydroxypropyl)-β-cyclodextrin (CD) in PBS. Doses of the analogues 
were set at 10mg/kg and the dose for TN14003 was set at 300 μg/kg. The TN14003 dose was set 
lower for this experiment because it was found that 300 μg/kg gave the maximum efficacy at 
minimum concentration in breast cancer metastasis in an animal model. The mice were dosed 30 
minutes after the carrageenan injection and then once a day following the initial dose. The mice 
were sacrificed 74 hours after inflammation was induced and two hours after the last injection of 
the selected analogues. The hind paws of the mice were photographed and calipers were used to 
measure the thickness of the paw from front to back. To quantify the edema, the measurement 
from the untreated paw was subtracted from the volume of the treated paw. The inflammation 
suppression percentage was determined by comparing the analogue treated groups to the control 
group. Each analogue was tested in quintuplicate using the above procedure.127, 131 Paw tissue slices 
were also collected and stained with H&E. Tissue slices were scanned and digitized by 
NanoZoomer 2.0 HT. The software NDP.view 2 was used to view the slices in detail. 
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5.2 Docking Studies 
5.2.1 Schrodinger Small Molecule Suite 
Schrodinger Small Molecule Suite 
The structure of the target receptor CXCR4, PDB-ID 3ODU, was retrieved from the RCSB 
Protein Data Bank.50 Docking calculations were performed by the Schrodinger suite with default 
settings unless otherwise indicated. The Protein Preparation Wizard was used to prepare the 
CXCR4 protein for docking. CXCR4 along with its co-crystallized ligand IT1t went through a 
preprocess procedure with the additional options to fill in missing side chains and loops using 
Prime and removing waters beyond 5Å from heteroatom groups. The heterostate for the co-
crystallized ligand was generated using Epik. The PROPKA feature was utilized to optimize the 
hydrogen bond network at a physiological pH. After hydrogen bond optimization, water molecules 
were removed with less than 3 H-bonds to non-waters. The protein was then energetically 
minimized using a default constraint of 0.3Å RMSD and OPLS 2005 force field. Ligands were 
prepared by the LigPrep function of the Schrodinger Suite with default parameters in the gas phase. 
Epik generated possible ionization states of the ligands at physiological pH. Receptor grid 
generation was performed by inputting the prepared receptor directly from the protein preparation 
wizard. Docking was performed using the Extra Precision (XP) feature of the GLIDE program. 
Ligands were docked flexibly in the rigid protein devoid of the IT1t ligand and were ranked based 
on their GLIDE docking score. 
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5.2.2 Autodock Vina 
The structure of the target receptor CXCR4, PDB-ID 3ODU, was retrieved from the RCSB 
Protein Data Bank.50 Docking calculations were performed AutoDock Vina and default settings 
were used unless otherwise specified. The protein in PDB form was uploaded into the program. 
The B dimer of the protein was then selected and removed to create a monomer. The monomer 
was then exported as a macromolecule, converting it to a PDBQT file. The gridbox was then 
selected; the initial gridbox had the following parameters: center_x = 16.807, center_y = -6.232, 
center_z = 69.119, size_x = 28, size_y = 28, size_z = 28, spacing = 1 angstrom. The biased gridbox 
had the following parameters: center_x = 19.717, center_y = -6.232, center_z = 69.53, size_x = 
22, size_y = 20, size_z = 14, spacing = 1 angstrom. Ligands were uploaded into Autodock as PDB 
files. Once inputted, charges were assigned automatically. Ligand was then exported as a PDBQT 
file. The PDBQT files were then coded in the configuration files labeled as ligand and receptor 
with an exhaustiveness of 16. The compounds were then docked in AutoDock Vina and the 
resulting log files were retained. 
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5.3 Chemistry 
The 1H NMR (400 MHz) and 13C NMR (100MHz) spectra were recorded on a Bruker Ac 
400 FT NMR spectrometer in deuterated chloroform (CDCl3). All chemical shifts were reported 
using parts per million (ppm). Mass spectra were recorded on a JEOL spectrometer at Georgia 
State University Mass Spectrometry Center. Detailed syntheses for the 2,5-Thiophene analogues 
can be found in the thesis of Francisco Garcia.148 
 
5.3.1 General Procedure for the Synthesis of the 2,6-Pyradine Analogues (2).  
To a solution of pyridine-2,6-dicarbaldehyde (50 mg, 0.37 mmol) in methanol (2 mL) was 
added the aniline derivative of choice (0.81 mmol) and ZnCl2 (100 mg, 0.74 mmol).  The solution 
was stirred for two hours at room temperature. NaBH3CN (46.5mg, 0.81 mmol) was then added 
and the solution as stirred overnight.  The crude product was purified by column chromatography. 
 
2,6-Bis(anilinomethyl)pyridine, (2a) Product purified using a 1:1 Hexane/Ethyl Acetate solvent 
system and was obtained in 37% yield as an off-white semi-solid. 1H NMR (400 MHz, CDCl3): δ 
ppm 4.38 (s, 4H), 6.59 (d, J = 7.8 Hz, 4H), 6.65 (t, J = 7.2 Hz, 2H), 7.06 - 7.15 (m, 6 H), 7.49 (t, 
J = 7.7 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ ppm 158.1, 148.0, 137.3, 129.3, 119.9, 117.7, 
113.1, 49.3; HRMS: m/z [M + H]+ calcd for C19H19N3: 290.1657, found: 290.1657. 
2,6-Bis(2-methylanilinomethyl)pyridine, (2b) The product was obtained in a 7:1 Hexanes/Ethyl 
Acetate solvent system and was obtained as an orange oil in 21% yield. 1H NMR (400 MHz, 
CDCl3): δ ppm 2.25 (s, 6H), 4.52 (s, 4H), 6.60 (d, J = 7.83 Hz, 2H), 6.68 (t, J = 7.33 Hz, 2H), 7.05 
- 7.14 (m, 4H), 7.22 (d, J = 7.83 Hz, 2H), 7.60 (t, J = 7.71 Hz, 1H); 13C NMR (100 MHz, CDCl3): 
δ ppm 158.02, 145.84, 137.26, 130.08, 127.13, 122.27, 119.99, 117.22, 110.14, 49.22, 17.59; 
HRMS: m/z [M + H]+ calcd for C21H23N3: 318.1965, found: 318.1958.  
66 
2,6-Bis(3-methylanilinomethyl)pyridine, (2c) The product was purified via flash 
chromatography using DCM as a solvent and was obtained as an orange oil in 50% yield. 1H NMR 
(400 MHz, CDCl3): δ ppm 2.26 (s, 6 H) 4.42 (s, 4 H) 6.42 - 6.52 (m, 4 H) 6.54 (d, J=7.33 Hz, 2 
H) 7.06 (t, J=7.58 Hz, 2 H) 7.17 (d, J=7.58 Hz, 2 H) 7.54 (t, J=7.58 Hz, 1 H); 13C NMR (100 MHz, 
CDCl3): δ ppm 158.23, 148.06, 139.06, 137.26, 129.20, 119.86, 118.61, 113.95, 110.23, 49.30, 
21.70. HRMS: m/z [M+ Z]+ calcd for C21H23N3 : 318.1965, found: 318.1965. 
2,6-Bis(4-methylanilinomethyl)pyridine, (2d) The product was purified via flash 
chromatography using DCM as a solvent  and was obtained was a yellow-orange solid in 34% 
yield. 1H NMR (400 MHz, CDCl3): δ ppm 2.24 (s, 6 H) 4.43 (s, 4 H) 6.59 (d, J=8.34 Hz, 4 H) 6.99 
(d, J=8.08 Hz, 4 H) 7.19 (d, J=7.83 Hz, 2 H) 7.56 (t, J=7.71 Hz, 1 H); 13C NMR (100 MHz, CDCl3): 
δ ppm 158.36, 145.70, 137.22, 129.78, 126.84, 119.85, 113.27, 49.64, 20.42. HRMS: m/z [M+ Z]+ 
calcd for C21H23N3 : 318.1965, found: 318.1962. 
2,6-Bis(2-ethylanilinomethyl)pyridine, (2e) The product was purified in a 1:1 Hexanes/Ethyl 
Acetate solvent system and was obtained in 53% yield as a brown solid. 1H NMR (400 MHz, 
CDCl3): δ ppm 1.31 (t, J = 7.45 Hz, 6H), 2.60 (q, J = 7.58 Hz, 4H), 4.52 (s, 4H),  6.61 (d, J = 7.83 
Hz, 2H), 6.73 (t, J = 7.33 Hz, 2H), 7.06 - 7.14 (m, 4H), 7.18 - 7.25 (m, 2H), 7.58 (t, J = 7.71 Hz, 
1H); 13C NMR (100 MHz, CDCl3): δ ppm 158.17, 145.32, 137.29, 127.89, 127.04, 119.98, 117.43, 
110.50, 49.36, 23.98, 12.92. HRMS: m/z [M + H]+ calcd for C23H27N3: 346.2278, found: 346.2276. 
2,6-Bis(3-ethylanilinomethyl)pyridine, (2f) The product was purified in a 3:1 Hexanes/Ethyl 
Acetate solvent system and was obtained as an orange oil in 23% yield. 1H NMR (400 MHz, 
CDCl3): δ ppm 1.18 - 1.24 (m, 6H), 2.56 (d, J = 6.32 Hz, 4H), 4.46 (br. s., 4H), 6.52 (d, J = 14.65 
Hz, 4H), 6.59 (br. s., 2H), 7.02 - 7.15 (m, 2H), 7.21 (d, J = 4.04 Hz, 2H), 7.51 - 7.62 (m, 1H); 13C 
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NMR (100 MHz, CDCl3): δ ppm 158.15, 148.10, 145.45, 137.20, 129.19, 119.83, 117.36, 112.80, 
110.34, 49.31, 29.02, 15.57; HRMS: m/z [M + H]+ calcd for C23H27N3: 346.2278, found: 346.2285. 
2,6-Bis(4-ethylanilinomethyl)pyridine, (2g) The product was purified in a 7:1 Hexanes/Ethyl 
Acetate solvent system and was obtained in 11% yield as an orange oil; 1H NMR (400 MHz, 
CDCl3): δ ppm 1.18 (t, J = 7.6 Hz, 6H), 2.50 - 2.57 (m, 4H), 4.41 (s, 4H), 6.59 (d, J = 8.3 Hz, 4H), 
6.97 (d, J= 8.1 Hz, 2H), 7.01 (d, J = 8.3 Hz, 4H), 7.53 (t, J = 7.7 Hz, 1H); 13C NMR (100 MHz, 
CDCl3): δ ppm 158.4, 146.0, 137.3, 133.6, 128.7, 119.9, 115.3, 113.3, 49.7, 28.0, 16.02. HRMS: 
m/z [M + H]+ calcd for C23H27N3: 346.2283, found: 346.2291. 
2,6-Bis(2-fluoroanilinomethyl)pyridine, (2h) The product was purified in a 3:1 Hexanes/Ethyl 
Acetate solvent system and was obtained in 7% yield as an orange oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 4.51 (br. s., 4H), 6.59 - 6.74 (m, 4H), 6.88 - 7.07 (m, 4H), 7.24 (d, J = 5.05 Hz, 
2H), 7.61 (d, J = 6.06 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ ppm 157.81, 152.93, 137.39, 
136.33, 124.56, 119.85, 116.96, 114.57, 112.50, 48.90; HRMS: m/z [M + H]+ calcd for 
C19H17N3F2: 326.1463, found: 326.1451. 
2,6-Bis(3-fluoroanilinomethyl)pyridine, (2i) Product was purified in a 3:1 Hexanes/Ethyl 
Acetate solvent system and was obtained in 62% yield as a brown semi-solid. 1H NMR (400 MHz, 
CDCl3): δ ppm 4.34 (s, 4H), 6.21 - 6.40 (m, 6H), 6.95 - 7.06 (m, 2H), 7.10 (d, J = 7.8 Hz, 2H), 
7.51 (t, J = 7.71 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ ppm 165.4, 162.9, 157.5, 149.8, 149.7, 
137.4, 130.3,120.1, 109.0, 104.2, 104.0, 99.9, 99.6, 48.9; HRMS: m/z [M + H]+ calcd for 
C19H17N3F2: 326.1469, found: 326.1462. 
2,6-Bis(4-fluoroanilinomethyl)pyridine, (2j) Product purified using a 3:1 Hexanes/Ethyl Acetate 
solvent system and was obtained in 34% yield as a brown semi-solid; 1H NMR (400 MHz, CDCl3): 
δ ppm 4.33 (s, 4H), 6.51 (dd, J = 8.72, 4.17 Hz, 4H), 6.81 (t, J = 8.59 Hz, 4H), 7.12 (d, J = 7.58 
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Hz, 2 H), 7.52 (t, J = 7.71 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ ppm 158.0, 157.2, 154.8, 
137.4, 137.2, 120.0,115.9, 115.7, 115.6, 115.5, 114.3, 113.5, 113.4, 49.9; HRMS: m/z [M + H]+ 
calcd for C19H17N3F2: 326.1469, found: 326.1462. 
2,6-Bis(2-chloroanilinomethyl)pyridine, (2k) The product was purified in a 3:1 Hexane/Ethyl 
Acetate solvent system and was obtained in 39% yield as a yellow solid. 1H NMR (400 MHz, 
CDCl3): δ ppm 4.54 (d, J = 5.05 Hz, 4H), 6.61 - 6.69 (m, 4H), 7.10 (t, J = 7.45 Hz, 2H), 7.21 (d, 
J = 7.58 Hz, 2H), 7.28 (d, J = 7.58 Hz, 2H), 7.61 (t, J = 7.71 Hz, 1H); 13C NMR (100 MHz, 
CDCl3): δ ppm 157.64, 143.70, 137.42, 139.18, 137.80, 119.83, 119.49, 117.45, 111.63, 48.94. 
HRMS: m/z [M + H]+ calcd for C19H17N3Cl2: 358.0872, found: 358.0877. 
2,6-Bis(3-chloroanilinomethyl)pyridine, (2l) Product was purified in a 4:1 Hexanes/Ethyl 
Acetate solvent system and was obtained in 14% yield as a yellow semi-solid; 1H NMR (400 MHz, 
CDCl3): δ ppm 4.36 (s, 4 H), 6.46 (dd, J = 8.1, 1.0 Hz, 2 H), 6.58 (s, 2 H) 6.61 (d, J = 7.8 Hz, 2 
H), 7.01 (t, J = 8.0 Hz, 2 H), 7.12 (d, J = 7.6 Hz, 2 H), 7.54 (t, J = 7.71 Hz, 1 H); 13C NMR (100 
MHz, CDCl3): δ ppm 157.4, 149.0, 137.5, 135.1, 130.3, 120.1, 117.5, 112.7, 111.4, 48.9. HRMS: 
m/z [M + H]+ calcd for C19H17N3Cl2: 358.0854, found: 358.0864. 
2,6-Bis(4-chloroanilinomethyl)pyridine, (2m) Product was purified in a 4:1 Hexanes/Ethyl 
Acetate solvent system and was obtained in 15% yield as a yellow solid; mp 116-118°C. 1H NMR 
(400 MHz, CDCl3): δ ppm 4.36 (br, s, 4H), 6.51 (d, J = 8.34 Hz, 4H), 7.06 (d, J = 8.34 Hz, 4H), 
7.12 (d, J = 7.6 Hz, 2H), 7.54 (t, J = 7.7 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ ppm 157.6, 
146.4, 137.4, 129.1, 122.3, 120.0, 114.2, 49.2. HRMS: m/z [M + H]+ calcd for C19H17N3Cl2: 
358.0872, found: 358.0864 
2,6-Bis(2-methoxyanilinomethyl)pyridine, (2n) The product was purified in a 7:1 Hexane/Ethyl 
Acetate solvent system and was obtained in 51% yield as a brown solid; mp 112-114°C. 1H NMR 
69 
(400 MHz, CDCl3): δ ppm 3.81 (s, 6 H), 4.43 (s, 4 H), 6.49 (d, J = 7.58 Hz, 2H), 6.58 - 6.64 (m, 
2H), 6.70 - 6.79 (m, 4H), 7.14 (d, J = 7.8 Hz, 2H), 7.48 (t, J = 7.7 Hz, 1H); 13C NMR (100 MHz, 
CDCl3): δ ppm 158.7, 147.0, 137.9, 137.3, 121.3, 119.6, 116.7, 110.3, 109.5, 55.5, 49.4. HRMS: 
m/z [M + H]+ calcd for C21H23N3O2: 350.1869, found: 350.1862. 
2,6-Bis(3-methoxyanilinomethyl)pyridine, (2o) The product was purified in a 3:1 Hexanes/Ethyl 
Acetate solvent system and was obtained in 16% yield as an off white semisolid. 1H NMR (400 
MHz, CDCl3): δ ppm 3.76 (br. s., 6H), 4.45 (br. s., 4H), 6.23 (br. s., 2H), 6.30 (m, 4H), 7.09 (d, J 
= 3.28 Hz, 2H), 7.20 (m, 2H), 7.59 (m, 1H); 13C NMR (100 MHz, CDCl3): δ ppm 160.79, 157.91, 
149.30, 137.28, 130.00, 119.89, 106.18, 102.75, 99.03, 55.08, 49.19. HRMS: m/z [M + H]+ calcd 
for C21H23N3O2: 350.1863, found: 350.1854. 
2,6-Bis(4-methoxyanilinomethyl)pyridine, (2p) Product was purified in two silica columns. The 
fist was purified in a solution of 9:1 DCM/Methanol. The compound was then further purified in 
4:5 solution of Hexanes/Ethyl Acetate. Product was obtained in 30% yield as a brown solid; mp 
63-65°C. 1H NMR (400 MHz, CDCl3): δ ppm 3.66 (s, 6 H), 4.33 (s, 4 H), 6.55 (d, J = 8.84 Hz, 4 
H), 6.70 (d, J = 8.84 Hz, 4 H), 7.12 (d, J = 7.58 Hz, 2 H), 7.49 (t, J = 7.7 Hz, 1 H); 13C NMR (100 
MHz, CDCl3): δ ppm 158.39, 152.25, 142.22, 137.20, 119.94, 114.90, 114.36, 55.79, 50.24; 
HRMS: m/z [M + H]+ calcd for C21H23N3O2 : 350.1869, found: 350.1865.
 
2,6-Bis(2-trifluoromethylanilinomethyl)pyridine, (2q) The product was purified in a 7:1 
Hexane/Ethyl Acetate solvent system and was obtained in 19% yield as an off white solid. 1H 
NMR (400 MHz, CDCl3): δ ppm 4.55 (d, J = 5.05 Hz, 4H), 6.63 - 6.79 (m, 4H), 7.20 (d, J = 7.58 
Hz, 2H), 7.32 (t, J = 7.71 Hz, 2H), 7.47 (d, J = 7.58 Hz, 2H), 7.61 (t, J = 7.71 Hz, 1H); 13C NMR 
(100 MHz, CDCl3): δ ppm 157.32, 145.14, 137.58, 133.14, 126.72, 126.67, 119.77, 116.27, 
113.66, 112.26, 48.69. HRMS: m/z [M + H]+ calcd for C21H17F6N3: 426.1401, found: 426.1399. 
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2,6-Bis(3-trifluoromethylanilinomethyl)pyridine, (2r) The product was purified in a 3:2 
Hexanes/Ethyl Acetate solvent system and was obtained in 50% yield as an off white solid. 1H 
NMR (400 MHz, CDCl3): δ ppm 4.46 (br. s., 4 H) 6.78 (d, J=8.08 Hz, 2 H) 6.87 (br. s., 2 H) 6.95 
(d, J=7.58 Hz, 2 H) 7.19 (d, J=7.83 Hz, 2 H) 7.25 (t, J=1.00 Hz, 2 H) 7.61 (t, J=7.71 Hz, 1 H); 13C 
NMR (100 MHz, CDCl3): δ ppm 157.24, 148.06, 137.51, 131.75, 129.71, 125.74, 123.03, 120.20, 
116.02, 114.05, 109.23, 48.80. HRMS: m/z [M + H]+ calcd for C21H17F6N3: 426.1399, found: 
426.1384. 
2,6-Bis(4-trifluoromethylanilinomethyl)pyridine, (2s) The product was purified in a 2:1 
Hexanes/Ethyl Acetate solvent system and was obtained in 61% yield as a light orange semi-solid. 
1H NMR (400 MHz, CDCl3): δ ppm 4.49 (s, 4 H) 6.65 (d, J=8.34 Hz, 4 H) 7.20 (d, J=7.83 Hz, 2 
H) 7.41 (d, J=8.34 Hz, 4 H) 7.63 (t, J=1.00 Hz, 1 H); 13C NMR (100 MHz, CDCl3): δ ppm 157.15, 
150.28, 137.59, 126.68, 126.32, 123.64, 120.15, 112.21, 48.46. HRMS: m/z [M + H]+ calcd for 
C21H17F6N3: 426.1399, found: 426.1381.  
2,6-Bis(4-thiomethylanilinomethyl)pyridine (2t) The product was purified in a 3:1 
Hexanes/Ethyl Acetate solvent system and was obtained in 14% yield as a white solid; 1H NMR 
(400 MHz, CDCl3): δ ppm 2.41 (s, 6 H) 4.44 (br. s., 4 H) 6.61 (d, J=8.34 Hz, 4 H) 7.16 - 7.31 (m, 
6 H) 7.59 (t, J=7.71 Hz, 1 H); 13C NMR (100 MHz, CDCl3): δ ppm 19.02, 49.12, 113.70, 119.94, 
124.61, 131.34, 137.30, 146.70, 157.80. HRMS: m/z [M + H]+ calcd for C21H24N3S2: 382.1206, 
found: 382.1404. 
2,6-Bis(3-nitroanilinomethyl)pyridine, (2u) The product was purified using a 30:1 
DCM/Methanol solvent system and was obtained in 34% yield as a yellow-orange solid; mp 147-
149°C. 1H NMR (400 MHz, CDCl3): δ ppm 4.54 (d, J = 5.05 Hz, 4H), 6.96 (d, J = 8.08 Hz, 2H), 
7.24 (br s, 2H), 7.31 (t, J = 8.1 Hz, 2H), 7.49 (br s, 2 H), 7.56 (d, J = 8.08 Hz, 2H), 7.65 - 7.71 (m, 
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1H); 13C NMR (100 MHz, CDCl3): δ ppm 156.8, 148.6, 137.7, 129.8, 120.4, 119.2, 112.4, 106.6, 
48.7. HRMS: m/z [M + H]+ calcd for C19H17N5O4: 380.1359, found: 380.1358. 
2,6-Bis(4-nitroanilinomethyl)pyridine, (2v) The product was purified using a 10:1 
DCM/Methanol soluvent system and was obtained in 10% yield as a yellow semi-solid; 1H NMR 
(400 MHz, CDCl3): δ ppm 4.51 (d, J = 5.1 Hz, 4H), 6.56 (d, J = 9.1 Hz, 4H), 7.17 (d, J = 7.8 Hz, 
2H), 7.64 (t, J=7.71 Hz, 1H), 8.05 (d, J=9.09 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ ppm 156.1, 
152.7, 137.9, 126.4, 120.5, 111.6, 48.9. HRMS: m/z [M + H]+ calcd for C19H18N5O4: 380.1359, 
found: 380.1359. 
2,6-Bis(morpholinylmethyl)pyridine (2w) The product purified in a 25:1 DCM/Methanol 
solvent system and was obtained was a white semi-solid in 1% yield. 1H NMR (400 MHz, CDCl3): 
δ ppm 7.73 (1H t), 7.47 (2H d), 5.30 (4H s), 2.60 (8H m), 1.65 (8H m), 1.50 (4H, m); 13C NMR 
(100 MHz, CDCl3): δ ppm 152.75, 137.55, 123.65, 120.96, 60.43, 63.80, 25.68, 25.11, 23.78. 
HRMS: m/z [M + H]+ calcd for C15H23N3O2: 278.1863, found: 278.1852. 
2,6-Bis(pyrrolidinylmethyl)pyridine (2x) The product was purified in a 5:1 DCM:Methanol 
solvent system and was obtained was a orangeish oil in 9% yield. 1H NMR (400 MHz, CDCl3): δ 
ppm 7.59 (t, J=7.7 Hz, 1H), 7.29 (s, 1H), 7.27 (s, 1H), 3.60 (s, 4H), 2.42-2.44 (m, 8H), 1.55-1.61 
(m, 8H), 1.40-1.46 (m, 4H); 13C NMR (100 MHz, CDCl3): δ ppm 158.71, 136.67, 121.20, 65.57, 
54.99, 26.20, 24.52. HRMS: m/z [M+H]+ calcd for C15H24N3: 246.1965, found: 246.1956. 
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5.3.2 General Procedure for the Synthesis of the 2,5-Furan Analogues (4) 
 
General Procedure for the Synthesis of the 2,5-furan-based analogues (4). To a solution of 
methanol, 50 mg (0.4029 mmol) of furan-2.5-dicarbaldehyde was combined in a dry vial with the 
aniline derivative of choice (0.8865 mmol) and 75.963 mg (1.2088 mmol) of sodium 
cyanoborohydride (NaBH3CN). The solution was stirred for five minutes at room temperature 
before 164.578 mg (1.2088 mmol) of zinc chloride (ZnCl2) was added. The solution was then 
stirred for two hours and purified by flash chromatography. 
 
2,5-Bis(anilinomethyl)furan, (4a) Product was purified in a 7:1 Hexanes/Ethyl Acetate solvent 
system and was obtained in 38% yield as a yellow oil. 1H NMR (400 MHz, CDCl3): δ ppm ppm 
4.27 (s, 4 H) 6.15 (s, 2 H) 6.66 (d, J=7.58 Hz, 4 H) 6.74 (t, J=7.33 Hz, 2 H) 7.18 (t, J=7.96 Hz, 4 
H); 13C NMR (100 MHz, CDCl3): δ ppm 152.11, 147.58, 129.22, 118.04, 113.18, 107.80, 41.49. 
HRMS: m/z [M + H]+ calcd for C18H19ON2: 279.1492, found: 279.1487. 
2,5-Bis(2-methylanilinomethyl)furan, (4b) The product was purified in a 13:1 solvent system 
and was obtained as a yellow solid in 35% yield. 1H NMR (400 MHz, CDCl3): δ ppm 2.14 (s, 6 
H) 3.84 (br s, 2 H) 4.33 (s, 4 H) 6.17 (s, 2 H) 6.63 - 6.75 (m, 4 H) 7.00 - 7.17 (m, 4 H); 13C NMR 
(100 MHz, CDCl3): δ ppm 152.22, 145.56, 130.14, 127.07, 122.34, 117.61, 110.13, 107.83, 41.50, 
17.49. HRMS: m/z [M + H]+ calcd for C20H23ON2 : 307.1805, found: 307.1792.  
2,5-Bis(3-methylanilinomethyl)furan, (4c) The product was purified in a 3:1 Hexanes/Ethyl 
Acetate solvent system and was obtained as a light orange solid in 49% yield. 1H NMR (400 MHz, 
CDCl3): δ ppm2.27 (s, 6 H) 4.25 (s, 4 H) 6.13 (s, 2 H) 6.42 - 6.50 (m, 4 H) 6.56 (d, J=7.58 Hz, 2 
H) 7.06 (t, J=1.00 Hz, 2 H); 13C NMR (100 MHz, CDCl3): δ ppm 152.17, 147.64, 138.98, 129.9, 
73 
118.97, 114.01, 110.27, 107.73, 41.53, 21.61. HRMS: m/z [M+ Z]+ calcd for C20H23ON2 : 
307.1817, found: 307.1810. 
2,5-Bis(4-methylanilinomethyl)furan, (4d) The product was purified in a 3:1 Hexanes/Ethyl 
Acetate solvent system and was obtained as an orange solid in 49% yield. 1H NMR (400 MHz, 
CDCl3): δ ppm 2.22 (s, 6 H) 4.21 (s, 4 H) 6.10 (s, 2 H) 6.56 (d, J=8.08 Hz, 4 H) 6.97 (d, J=7.83 
Hz, 4 H); 13C NMR (100 MHz, CDCl3): δ ppm 152.25, 145.33, 129.68, 127.21, 113.38, 107.67, 
41.82, 20.40. HRMS: m/z [M+ Z]+ calcd for C20H22ON2Na: 329.1617, found: 329.1624. 
2,5-Bis(2-ethylanilinomethyl)furan, (4e) The product was purified in a 9:1 Hexanes/Ethyl 
Acetate solvent system and was obtained in 44% yield as a yellow oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 1.24 (br d, J=5.56 Hz, 6 H) 2.44 - 2.56 (m, 4 H) 3.94 (br s, 2 H) 4.33 (br s, 4 H) 
6.16 (br s, 2 H) 6.66 - 6.78 (m, 4 H) 7.05 - 7.16 (m, 4 H); 13C NMR (100 MHz, CDCl3): δ ppm 
152.28, 144.98, 128.02, 127.92, 126.93, 117.81, 110.52, 107.79, 41.59, 23.79, 12.90. HRMS: m/z 
[M + H]+ calcd for C22H27ON2: 335.2118, found: 335.2103. 
2,5-Bis(3-ethylanilinomethyl)furan, (4f) The product was purified in a 9:1 Hexanes/Ethyl 
Acetate solvent system and was obtained as an orange oil in 42% yield. 1H NMR (400 MHz, 
CDCl3): δ ppm 1.21 (br d, J=5.31 Hz, 6 H) 2.51 - 2.63 (m, 4 H) 3.93 (br s, 2 H) 4.26 (br s, 4 H) 
6.14 (br s, 2 H) 6.45 - 6.54 (m, 4 H) 6.54 - 6.65 (m, 2 H) 7.05 - 7.14 (m, 2 H); 13C NMR (100 
MHz, CDCl3): δ ppm 152.20, 147.70, 145.40, 129.15, 117.78, 112.93, 110.47, 107.75, 41.57, 
29.00, 15.51. HRMS: m/z [M + H]+ calcd for C22H27ON2: 335.2118, found: 335.2103. 
2,5-Bis(4-ethylanilinomethyl)furan, (4g) The product was purified in a 7:1 Hexanes/Ethyl 
Acetate solvent system and wass obtained in 27% yield as an orange oil; 1H NMR (400 MHz, 
CDCl3): δ ppm 1.18 (t, J=7.58 Hz, 6 H) 2.54 (q, J=7.41 Hz, 4 H) 4.24 (s, 4 H) 6.12 (s, 2 H) 6.60 
(d, J=8.34 Hz, 4 H) 7.01 (d, J=8.08 Hz, 4 H); 13C NMR (100 MHz, CDCl3): δ ppm 152.28, 145.58, 
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133.88, 128.52, 113.35, 107.69, 41.83, 27.93, 15.91. HRMS: m/z [M + H]+ calcd for C22H27ON2: 
335.2118, found: 335.2111. 
2,5-Bis(2-fluoroanilinomethyl)furan, (4h) The product was purified in a 20:1 Hexanes/Ethyl 
Acetate solvent system and was obtained in 40% yield as an yellow oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 4.28 (br s, 4 H) 6.14 (s, 2 H) 6.59 - 6.78 (m, 4 H) 6.90 - 7.05 (m, 4 H); 13C NMR 
(100 MHz, CDCl3): δ ppm 152.84, 151.84, 150.47, 136.04, 135.93, 130.41, 126.93, 124.53, 
124.50, 118.58, 117.38, 117.31, 114.90, 114.40, 112.51, 107.94, 41.02. HRMS: m/z [M + H]+ 
calcd for C18H17ON2F2: 315.13, found: 315.1299. 
2,5-Bis(3-fluoroanilinomethyl)furan, (4i) Product was purified in 9:1 Hexanes/Ethyl Acetate 
solvent system and was obtained in 35% yield as an orange oil. 1H NMR (400 MHz, CDCl3): δ 
ppm 4.23 (s, 4 H) 6.15 (s, 2 H) 6.34 (dd, J=11.49, 1.64 Hz, 2 H) 6.37 - 6.45 (m, 4 H) 7.05 - 7.13 
(m, 2 H); 13C NMR (100 MHz, CDCl3): δ ppm 165.22, 162.80, 151.69, 149.35, 149.25, 130.35, 
130.25, 109.00, 108.98, 108.07, 104.53, 104.31, 99.95, 99.69, 41.27. HRMS: m/z [M + H]+ calcd 
for C18H17ON2F2: 315.1303, found: 315.1292. 
2,5-Bis(4-fluoroanilinomethyl)furan, (4j) Product was purified in 3:1 Hexanes/Ethyl Acetate 
solvent system and was obtained in 52% yield as an orange oil. 1H NMR (400 MHz, CDCl3): δ 
4.22 (s, 4 H) 6.13 (s, 2 H) 6.53 - 6.64 (m, 4 H) 6.88 (m, J=8.70, 8.70 Hz, 4 H); 13C NMR (100 
MHz, CDCl3): δ ppm 157.35, 155.00, 152.04, 143.88, 115.77, 115.55, 114.18, 114.11, 107.90, 
42.10. HRMS: m/z [M + H]+ calcd for C18H17ON2F2: 315.1294, found: 315.1303. 
2,5-Bis(2-chloroanilinomethyl)furan, (4k) The product was purified in a 12:1 Hexanes/Ethyl 
Acetate solvent system and was obtained in 6% yield. 1H NMR (400 MHz, CDCl3): δ ppm 4.35 
(br s, 4 H) 4.67 (br s, 2 H) 6.17 (br s, 2 H) 6.63 - 6.69 (m, 2 H) 6.73 (br s, 2 H) 7.12 (br s, 2 H) 
7.26 (br s, 2 H); 13C NMR (100 MHz, CDCl3): δ ppm 151.72, 143.42, 129.19, 127.76, 119.46, 
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117.89, 111.59, 107.98, 41.16. HRMS: m/z [M + H]+ calcd for C18H17ON2Cl2: 347.0712, found: 
347.0509. 
2,5-Bis(3-chloroanilinomethyl)furan, (4l) Product was purified in a 7:1 Hexanes/Ethyl Acetate 
solvent system and was obtained in 59% yield as an orange oil. 1H NMR (400 MHz, CDCl3): δ 
ppm 4.21 (4 H, s) 6.13 (2 H, s) 6.49 (2 H, d, J=8.34 Hz) 6.61 (2 H, br. s.) 6.69 (2 H, d, J=6.82 Hz); 
13C NMR (100 MHz, CDCl3): δ ppm 41.18, 108.10, 111.43, 112.79, 114.89, 117.83, 130.21, 
148.69, 151.67. HRMS: m/z [M + H]+ calcd for C18H17ON2Cl2: 347.0712, found: 347.0685. 
2,5-Bis(4-chloroanilinomethyl)furan, (4m) Product as purified in a 7:1 Hexanes/Ethyl Acetate 
solvent system and was obtained in 71% yield as an orange oil. 1H NMR (400 MHz, CDCl3): δ 
ppm 4.21 (4 H, s) 6.12 (2 H, s) 6.54 (4 H, d, J=8.59 Hz) 7.09 (4 H, d, J=8.59 Hz). 13C NMR (100 
MHz, CDCl3): δ ppm 41.26, 107.80, 114.06, 122.32, 28.85, 146.01, 151.69. HRMS: m/z [M + H]+ 
calcd for C18H17ON2Cl2: 347.0712, found: 347.0696. 
2,5-Bis(2-methoxyanilinomethyl)furan, (4n) The product was purified in a 9:1 Hexanes/Ethyl 
Acetate solvent system and was obtained in 29% yield as a white solid; 1H NMR (400 MHz, 
CDCl3): δ ppm 7.12 (t, J = 7.71 Hz, 2H), 7.06 (d, J = 7.07 Hz, 2H), 6.64 - 6.72 (m, 4H), 6.17 (s, 
2H), 4.33 (s, 4H), 2.14 (s, 6H); 13C NMR (100 MHz, CDCl3): δ ppm 152.22, 145.56, 130.14, 
127.07, 122.34, 117.61, 110.13, 107.83, 41.5, 17.49. HRMS: m/z [M + H]+ calcd for 
C20H22N2O3Na: 361.1528, found: 361.1537. 
2,5-Bis(3-methoxyanilinomethyl)furan, (4o) The product was purified in a 2:1 Hexane/Ethyl 
Acetate solvent system and was obtained in 30% yield as an orange oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 7.00 - 7.13 (m, 2H), 6.19 - 6.35 (m, 6H), 6.15 (s, 2H), 4.25 (s, 4H), 3.65 - 3.79 (m, 
6H); 13C NMR (100 MHz, CDCl3): δ ppm 160.74, 151.99, 148.98, 129.96, 107.87, 106.23, 103.09, 
99.20, 55.07, 41.45. HRMS: m/z [M + H]+ calcd for C20H23N2O3: 339.1676, found: 339.1687. 
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2,5-Bis(4-methoxyanilinomethyl)furan, (4p) Product was purified in a 7:1 Hexanes/Ethyl 
Acetate solvent system and was obtained in 35% yield as a brown solid. 1H NMR (400 MHz, 
CDCl3): δ ppm 3.74 (6 H, s) 4.22 (4 H, s) 6.13 (2 H, s) 6.63 (4 H, d, J=8.84 Hz) 6.78 (4 H, d, 
J=8.84 Hz); 13C NMR (100 MHz, CDCl3): δ ppm 152.58, 152.34, 141.77, 116.42, 114.81, 107.72, 
55.73, 42.52. HRMS: m/z [M + H]+ calcd for C20H23N2O3 : 339.1701, found: 339.1703.
 
2,5-Bis(2-trifluoromethylanilinomethyl)furan, (4q) The product was purified in a 13:1 
Hexanes/Ethyl Acetate solvent system and was obtained in 9% yield as a yellow oil. 1H NMR (400 
MHz, CDCl3): δ ppm 4.37 (br d, J=4.55 Hz, 4 H) 4.72 (br s, 2 H) 6.17 (s, 2 H) 6.70 - 6.88 (m, 4 
H) 7.31 - 7.41 (m, 2 H) 7.45 (br d, J=7.58 Hz, 2 H); 13C NMR (100 MHz, CDCl3): δ ppm 151.48, 
144.97, 133.06, 126.68, 116.66, 114.10, 112.18, 108.02, 41.06. HRMS: m/z [M + H]+ calcd for 
C20H17F6N2O: 415.1240, found: 415.1246. 
2,5-Bis(3-trifluoromethylanilinomethyl)furan, (4r) The product was purified in a 3:1 
Hexanes/Ethyl Acetate solvent system and was obtained in 60% yield as an orange oil. 1H NMR 
(400 MHz, CDCl3): δ ppm 7.20 - 7.24 (m, 2H), 6.95 - 6.98 (m, 2H), 6.86 (br. s., 2H), 6.76 - 6.80 
(m, 2H), 6.17 (s, 2H), 4.29 (s, 4H); 13C NMR (100 MHz, CDCl3): δ ppm 151.62, 147.67, 129.73, 
129.65, 117.97, 116.11, 114.46, 109.34, 108.23, 41.14. MS: m/z [M]+ calcd for C20H16F6N2O: 
413.1080. 
2,5-Bis(4-trifluoromethylanilinomethyl)furan, (4s) The product was purified in a 3:1 
Hexanes/Ethyl Acetate solvent system and was obtained in 33% yield as an orange oil. 1H NMR 
(400 MHz, CDCl3): δ ppm 7.41 (d, J=8.08 Hz, 4H), 6.66 (d, J=8.34 Hz, 4H), 6.18 (s, 2H), 4.32 
(s, 4H); 13C NM0R (100 MHz, CDCl3): δ ppm 151.54, 149.93, 126.64, 123.53, 119.80, 112.23, 
108.23, 40.94. HRMS: m/z [M+ Z]+ calcd for C20H16F6N2ONa: 437.1066, found: 437.1059.  
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2,5-Bis(4-thiomethylanilinomethyl)furan (4t) The product was purified in a 7:1 Hexanes/Ethyl 
Acetate solvent system and was obtained in 25% yield as an orange oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 2.40 (s, 6 H) 4.25 (s, 4 H) 6.14 (s, 2 H) 6.60 (d, J=8.59 Hz, 4 H) 7.20 (d, J=8.59 
Hz, 4 H). 13C NMR (100 MHz, CDCl3): δ ppm 151.94, 146.31, 131.12, 125.17, 113.81, 107.92, 
41.48, 18.87. HRMS: m/z [M + H]+ calcd for C20H23N2OS2: 371.1238, found: 371.1246. 
2,5-Bis(4-methypiperazin-1-ylmethyl)furan, (4u) The product was purified in a 30:1 
DCM/Methanol solvent system and was obtained as a yellow oil in 40% yield. 1H NMR (400 MHz, 
CDCl3): δ ppm 6.13 (s, 2H), 3.54 (s, 4H), 2.53 (m, J=16.17 Hz, 16H), 2.30 (s, 6H); 13C NMR (100 
MHz, CDCl3): δ ppm 151.09, 109.48, 54.89, 54.76, 52.48, 45.84. HRMS: m/z [M + H]+ calcd for 
C16H29N4O: 293.2336, found: 293.2323. 
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5.3.3 General Procedure for the Synthesis of the 3,4-Thiophene Analogues (8) 
Procedure for the Synthesis of Thiophene-3,4-dimethanol (6). 
The dimethanol compound was prepared according to a literature procedure151 where 500 
mg of thiophene-3,4-dicarboxylic acid (2.9mmol) was added to 10mL of dry THF in a dry round 
bottom flask and was chilled to 0°C. 17.375mL (17.375mmol) of diisobutylaluminimum hydride 
(139mL in 1M hexanes) was added to the flask and the solution was stirred at room temperature 
for 16 hours. The reaction was quenched with methanol and water and then 25mL of HCl was 
added to break up the solid chunks in the reaction. The solution as then extracted with ethyl acetate, 
washed with brine and dried with MgSO4. The solution was then evaporated under reduced 
pressure to give an orange oil in 77% yield. 
 
Procedure for the Synthesis of Thiophene-3,4-dialdehyde (7). The thiophene aldehyde 
was prepared using an adapted literature procedure152 where 2.0 g of Compound 6 (13.9 mmol) was 
added to a 100 mL solution of dry 1,4-dioxane. 6.0 g of dry activated MnO2 (69.00 mmol) was added and 
the mixture was refluxed under N2 for forty-five minutes at 96oC. The solution was filtered through a fritted 
filter funnel and was concentrated under reduced pressure to yield a light yellow solid in 90% yield. 1H 
NMR was used to confirm the structure with the literature characterization 
 
General Procedure for the Synthesis of the 3,4-bis(anilino)thiophene analogues (8). 
To a solution of methanol, 50mg (0.3568 mmol) of thiophene-3.4-dicarbaldehyde was combined 
in a dry vial with the aniline derivative of choice (0.7849 mmol), 145.68 mg (1.070 mmol) of zinc 
chloride (ZnCl2). The solution was stirred at room temperature overnight. The solution was 
reduced to dryness and was then dissolved in ethanol, where 67.24 mg (1.070 mmol) of sodium 
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cyanoborohydride (NaBH3CN) was added. The solution was then stirred overnight and purified 
by flash chromatography.  
 
3,4-Bis(anilinomethyl)thiophene, (8a) The product was purified in a 7:1 Hexanes/Ethyl Acetate 
solvent system and was obtained in this reaction was an brown semisolid in 4% yield. 1H NMR 
(400 MHz, CDCl3): δ ppm 7.24 (2H s), 7.18 (4H t), 6.65 (4H d), 6.44 (2H d), 4.31 (4H s); 13C 
NMR (100 MHz, CDCl3): δ ppm 147.94, 138.38, 129.30, 124.23, 117.98, 113.21, 42.89. HRMS: 
m/z [M + H]+ calcd for C18H19N2S: 291.0956, found: 291.0963. 
3,4-Bis(3-methylanilinomethyl)thiophene, (8b) The product was purified in a 20:1 
Hexanes/Ethyl Acetate solvent system and was obtained as an orange solid in 26% yield. 1H NMR 
(400 MHz, CDCl3): δ ppm 2.34 (6 H, s) 4.77 (4 H, s) 6.81 (2 H, d, J=7.83 Hz) 6.84 (2 H, s) 7.00 
(2 H, s) 7.18 - 7.28 (4 H, m); 13C NMR (100 MHz, CDCl3): δ ppm 21.83, 49.59, 114.71, 116.91, 
118.75, 120.29, 128.74, 138.62, 140.60, 151.66. HRMS: m/z [M + H]+ calcd for C20H23N2S: 
323.1576, found: 323.1561. 
3,4-Bis(4-methylanilinomethyl)thiophene, (8c) The product was purified in a 20:1 
Hexanes/Ethyl Acetate solvent system and was obtained as an orange solid in 19% yield. 1H NMR 
(400 MHz, CDCl3): δ ppm 2.33 (6 H, s) 4.77 (4 H, s) 6.90 (4 H, d, J=8.08 Hz) 7.01 (2 H, s) 7.80 
(4 H, d, J=8.34 Hz); 13C NMR (100 MHz, CDCl3): δ ppm 20.82, 49.67, 114.69, 120.05, 121.71, 
123.21, 129.47. HRMS: m/z [M + H]+ calcd for C20H23N2S: 323.1576, found: 323.1565. 
3,4-Bis(4-ethylanilinomethyl)thiophene, (8d) The product was purified in a 15:1 Hexanes/Ethyl 
Acetate solvent system and as obtained as an orange oil in 3% yield. 1H NMR (400 MHz, CDCl3): 
δ ppm 1.19 (t, J = 7.45 Hz, 6 H) 2.54 (q, J = 7.58 Hz, 4 H) 4.28 (s, 4 H) 6.60 (d, J = 8.08 Hz, 4 H) 
7.02 (d, J = 8.08 Hz, 4 H) 7.23 (s, 2 H); 13C NMR (100 MHz, CDCl3): δ ppm 147.94, 138.38, 
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129.30, 124.23, 117.98, 113.21, 42.89. HRMS: m/z [M + H]+ calcd for C22H27N2S: 351.1889, 
found: 351.1888. 
3,4-Bis(3-fluoroanilinomethyl)thiophene, (8e) The product was purified in a 7:1 Hexanes/Ethyl 
Acetate solvent system and was obtained as an off-white semi-solid in 12% yield. 1H NMR (400 
MHz, CDCl3): δ ppm 4.43 (br. s., 4 H) 6.21 - 6.66 (m, 8 H) 7.14 (d, J = 7.07 Hz, 2 H); 13C NMR 
(100 MHz, CDCl3): δ ppm 141.68, 137.70, 130.35, 124.53, 114.69, 107.13, 104.13, 99.97, 49.13. 
HRMS: m/z [M + H]+ calcd for C18H17N2SF2: 331.1061, found: 331.1075. 
3,4-Bis(4-fluoroanilinomethyl)thiophene, (8f) The product was purified in a 6:1 Hexane/Ethyl 
Acetate solvent system and was obtained as a yellowish semisolid in 15% yield. 1H NMR (400 
MHz, CDCl3): δ ppm 4.25 (s, 4 H) 6.49 - 6.61 (m, 4 H) 6.88 (t, J = 8.72 Hz, 4 H) 7.23 (s, 2 H); 
13C NMR (100 MHz, CDCl3): δ ppm 157.32, 144.26, 138.22, 124.40, 115.86, 115.64, 112.16, 
43.58. HRMS: m/z [M + H]+ calcd for C18H17N2SF2: 331.1072, found: 331.1075. 
3,4-Bis(3-chloroanilinomethyl)thiophene, (8g) Product was purified in a 15:1 Hexanes/Ethyl 
Acetate solvent system and was obtained in 31% yield as an off white oil. 1H NMR (400 MHz, 
CDCl3): δ ppm 4.26 (4 H, s) 6.48 (2 H, dd, J=8.21, 1.39 Hz) 6.60 (2 H, s) 6.69 (2 H, dd, J=0.80 
Hz) 7.06 (2 H, t, J=7.96 Hz); 13C NMR (100 MHz, CDCl3): δ ppm 42.60, 111.47, 112.76, 117.85, 
124.53, 130.27, 135.05, 137.64, 148.95. HRMS: m/z [M + H]+ calcd for C18H17N2Cl2S: 363.0484, 
found: 363.0466. 
3,4-Bis(4-chloroanilinomethyl)thiophene, (8h) Product was purified in a 15:1 Hexanes/Ethyl 
Acetate solvent system and was obtained in 23% yield as a brown solid. 1H NMR (400 MHz, 
CDCl3): δ ppm 4.26 (s, 4 H) 6.54 (d, J=8.84 Hz, 4 H) 7.11 (d, J=8.59 Hz, 4 H) 7.22 (s, 2 H); 13C 
NMR (100 MHz, CDCl3): δ ppm 146.39, 137.82, 129.15, 124.50, 122.67, 114.26, 42.97. HRMS: 
m/z [M + H]+ calcd for C18H17N2Cl2S: 363.0408, found: 363.0466. 
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3,4-Bis(3-trifluoromethylanilinomethyl)thiophene, (8i) The product was purified in a 10:1 
solvent system of Hexanes/Ethyl Acetate and was obtained in 20% yield as an orange oil. 1H NMR 
(400 MHz, CDCl3): δ ppm 4.32 (s, 4 H) 6.74 (d, J=8.08 Hz, 2 H) 6.82 (br. s., 2 H) 6.89 - 7.04 (m, 
2 H) 7.23 - 7.33 (m, 4 H); 13C NMR (100 MHz, CDCl3): δ ppm 147.95, 137.47, 131.48, 129.76, 
125.63, 125.77, 116.09, 114.50, 109.28, 42.61 HRMS: m/z [M + H]+ calcd for C20H17F6N2S: 
431.1011, found: 431.0994.  
3,4-Bis(4-trifluoromethylanilinomethyl)thiophene, (8j) The product was purified in a 10:1 
Hexanes/Ethyl Acetate solvent system and was obtained in 6% yield as a white semi-solid. 1H 
NMR (400 MHz, CDCl3): δ ppm 4.33 (br. s., 4 H) 6.62 (d, J=8.08 Hz, 4 H) 7.25 (s, 2 H) 7.40 
(d, J=8.34 Hz, 4 H); 13C NMR (100 MHz, CDCl3): δ ppm 150.17, 137.26, 126.73, 126.69, 126.66, 
124.77, 112.21, 42.36. HRMS: m/z [M + H]+ calcd for C20H17F6N2S: 431.1011, found: 431.0995.  
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5.3.4 General Procedure for the Synthesis of the 2,5-Pyrazine Analogues (14) 
Procedure for the Synthesis of 2,5-Dimethylpyrazine-1,4-dioxide (10) 
The dioxide compound was prepared from a literature procedure152 where 20.20mL 
(184.94 mmol) of 2,5-dimethyl pyrazine (9) was added to 50 mL of ethyl acetate. This solution 
was combined to a solution of m-CPBA (70% purity, 405.63 mmol) dissolved in 150 mL of ethyl 
acetate that had been washed with 150 mL of brine and dried over MgSO4. The mixture was stirred 
at room temperature for 24 hours and a white precipitate formed. The precipitate was then filtered 
and washed with 100 mL of ethyl acetate in triplicate. This compound was yielded in 90% percent 
as a white solid. 1H was used to confirm structure with the literature characterization. 
 
Procedure for the Synthesis of 2,5-Di(acetoxymethyl)pyrazine (11) 
The di(acetoxymethyl) compound was prepared from a literature procedure152 where 20 g 
of compound 10 (142.72 mmol) was added to 100 mL of acetic anhydride and was refluxed at 
158oC for seven hours. The solution was then stirred at room temperature for twelve hours. The 
resulting product was a black residue and was acquired by removing the acetic anhydride under 
reduced pressure. 500 mL of diethyl ether was added to the black residue and was stirred at room 
temperature for two hours. The solution was then filtered and the remaining residue was washed 
with 100 mL of diethyl ether. The filtrate was condensed under reduced pressure to yield a dark 
yellow residue. The residue was purified via flash column chromatography using a solution of 
40% ethyl acetate and 60% hexanes. This yellow product was then recrystallized from ethyl acetate 
and hexanes to yield a white solid in 16% yield. 1H NMR was used to confirm the structure with 
the literature characterization.  
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Procedure for the Synthesis of 2,5-Di(hydroxymethyl)pyrazine (12) 
The di(hydroxymethyl) compound was prepared from a literature procedure152 where 4.0 
g of compound 11 (17.84 mmol) was suspended in 100 mL of dry methanol. 0.8 g of NaOMe 
(14.80 mmol) was added. The solution was stirred at room temperature for three hours under N2. 
105 g of NH4Cl was added to quench the reaction and the methanol was removed under reduced 
pressure. The remaining residue was purified by flash chromatography using a solution of 10% 
methanol and 90% chloroform to yield a white solid in 91% yield. 1H NMR was used to confirm 
the structure with the literature characterization. 
 
Procedure for the Synthesis of 2,5-pyrazinedicarbaldehyde (13) 
The di(hydroxymethyl) compound was prepared from a literature procedure152 where 2.0 
g of compound 12 (14.27 mmol) was added to a 100 mL solution of dry 1,4-dioxane. 6.0 g of dry 
activated MnO2 (69.00 mmol) was added and the mixture was refluxed under N2 for forty-five 
minutes at 96oC. The solution was filtered through a fritted filter funnel and was concentrated 
under reduced pressure to yield a light yellow solid in 80% yield. 1H NMR was used to confirm 
the structure with the literature characterization. 
 
General Procedure for the Synthesis of the 2,5-pyrazinedicarbaldehyde analogues 
(14) 
To a solution of methanol, 32 mg of compound 13 (0.2351 mmol) was combined in a dry 
vial with the aniline derivative of choice (0.5172 mmol) and 96.02 mg (0.7053 mmol) of ZnCl2. 
The solution was stirred for two hours at room temperature before 44.32 mg (0.7053 mmol) of 
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NaBH3CN was added. The solution was then stirred overnight and purified by flash 
chromatography. 
 
3,4-Bis(anilinomethyl)pyrazine, (14a) The product was purified in a 1:1 Hexane/Ethyl Acetate 
solvent system and was obtained as an orange solid in 10% yield. 1H NMR (400 MHz, CDCl3): δ 
ppm 4.50 (s, 4 H) 6.68 (d, J=7.83 Hz, 4 H) 6.75 (t, J=7.33 Hz, 2 H) 7.19 (t, J=7.83 Hz, 4 H) 8.60 
(s, 2 H); 13C NMR (100 MHz, CDCl3): δ ppm 152.42, 147.42, 142.71, 129.37, 118.17, 113.18, 
47.08. HRMS: m/z [M + H]+ calcd for C18H19N4: 291.1604, found: 291.1599. 
3,4-Bis(3-methylanilinomethyl)pyrazine, (14b) The product was purified in a 1:1 Hexanes/Ethyl 
Acetate solvent system and was obtained as a brown solid in 4% yield. 1H NMR (400 MHz, 
CDCl3): δ ppm 8.59 (s, 2H), 7.07 (t, J=7.71 Hz, 2H), 6.23 - 6.67 (m, 6H), 4.49 (s, 4H), 2.27 (s, 
6H); 13C NMR (100 MHz, CDCl3): δ ppm 147.49, 146.34, 142.69, 139.18, 129.17, 119.47, 115.92, 
112.25, 47.13, 21.44. HRMS: m/z [M + H]+ calcd for C20H23N4: 319.1917, found: 319.1909. 
3,4-Bis(4-ethylanilinomethyl)pyrazine, (14b) The product was purified in a 1:1 Hexanes/Ethyl 
Acetate solvent system and was obtained as a brown solid in 5% yield. 1H NMR (400 MHz, 
CDCl3): δ ppm 1.18 (t, J=7.58 Hz, 6 H), 2.54 (d, J=7.58 Hz, 4 H), 4.48 (s, 4 H), 6.62 (d, J=8.08 
Hz, 4 H), 7.03 (d, J=8.08 Hz, 4 H), 8.9 (s, 2 H); 13C NMR (100 MHz, CDCl3): δ ppm 152.60, 
145.37, 142.72, 134.05, 128.67, 113.33, 47.45, 27.93, 15.91. HRMS: m/z [M + H]+ calcd for 
C22H27N4: 347.2230, found: 347.2225. 
3,4-Bis(4-fluoroanilinomethyl)pyrazine, (14d) The product was purified in a 1:1 Hexanes/Ethyl 
Acetate solvent system and was obtained as a light orange solid in 5% yield. 1H NMR: δ ppm 4.46 
(br. s., 4 H) 6.55 - 6.67 (m, 4 H) 6.90 (m, J=8.20, 8.20 Hz, 4 H) 8.58 (s, 2 H); 13C NMR: δ ppm 
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157.39, 155.05, 152.31, 143.71, 142.73, 115.94, 114.09, 114.02, 47.63. HRMS: m/z [M + H]+ 
calcd for C18H17N4F2: 327.1416, found: 327.1409. 
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1H NMR Spectrum for Compound 2f 
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8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
N
o
rm
a
liz
e
d
 I
n
te
n
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it
y
4.003.901.991.972.001.00
M03(d)
M02(d)
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TG16-1 final proton.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
4.052.001.951.961.991.960.98
M06(s)
M05(d)
M03(d)
M02(t)
M04(t)
M07(dd)
M01(s)
7
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7
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7
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TG17-1 final proton.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
4.003.973.842.021.00
M02(d)
M03(d)
M05(br. s.)
M01(t)
M04(d)
7
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4
7
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2
7
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3
7
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TG24 proton.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
6.193.662.001.973.992.051.03
M02(s)
M06(m)M04(m)
M01(s)
M05(m)M03(t)
M07(d)
7
.4
8
7
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TG93 PROTON.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
5.653.632.003.652.041.680.90
M02(br. s.)
M07(br. s.)
M05(m)
M06(br. s.)
M04(m)
M03(m)
M01(br. s.)
7
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9
7
.2
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TG14-2 Final proton.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
6.023.483.543.931.750.93
M05(s)
M06(s)
M04(d)
M02(d)
M03(d)
M01(t)
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TG90 PROTON.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
4.094.001.952.022.011.03
M06(d)
M03(t)
M04(d)
M05(t)
M07(m)
M01(d)
7
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TG29 proton.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
4.002.041.991.981.961.970.97
M05(d)
M06(t)
M04(br. s.)
M02(d)
M03(d)
M01(t)
M07(br. s.)
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TG28 2nd Spot PROTON.esp
8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
N
o
rm
a
liz
e
d
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n
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y
4.004.121.934.071.11
M03(d)
M01(t)
M02(d)
M05(s)
M04(d)
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TG37 dark spot 2.001.001.1r.esp
8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
N
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a
liz
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y
6.034.084.076.001.03
M05(m)
M01(t)
M03(br. s.)
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TG19-2 PROTON Final.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
N
o
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a
liz
e
d
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n
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n
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y
4.012.081.702.252.022.091.11
M03(br. s.)
M05(br. s.)
M07(d)
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M06(d)
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TG18-1 proton final.esp
8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
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0.15
0.20
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4.004.711.811.244.60
M04(d)
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M02(d)
8
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TG33 proton.esp
8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.05
0.10
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0.25
0.30
0.35
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0.55
0.60
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0.70
0.75
N
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a
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e
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7.954.408.001.831.05
M05(m)
M04(t)
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TG39 PROTON.esp
16 14 12 10 8 6 4 2 0 -2 -4
Chemical Shift (ppm)
0
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0.04
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0.11
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M05(t)
M02(m)
M03(s)
M01(t)
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TG50 PROTON.esp
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
N
o
rm
a
liz
e
d
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n
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n
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y
4.171.994.072.014.00
M05(t) M03(d)
M04(t)
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TG103 PROTON.esp
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
N
o
rm
a
liz
e
d
 I
n
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n
s
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y
6.104.041.963.941.992.00
M06(t)
M04(m)
M05(d)
M01(s)
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TG54 proton.esp
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
6.823.891.824.002.022.22
M06(m)
M05(d)
M03(s)
M04(t)
M01(s)
M02(s)
7
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8
7
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TG55 PROTON.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
6.594.091.924.204.00
M05(d)
M03(s)
M04(d)
M02(s)
M01(s)
6
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TG107 proton.esp
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
6.003.903.781.843.773.76
M04(br. s.)
M02(m)
M01(s)
M06(q)
M03(m)
M05(t)
7
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TG108 proton.esp
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
6.114.024.031.925.932.00
M01(br. s.)
M04(t)
M02(br. s.)
M03(q)
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M05(m)
7
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TG51 proton.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
9.504.623.761.803.624.00
M06(d)
M05(d)
M01(t)
M04(s)
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M02(q)
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TG101 PROTON.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
4.631.522.001.883.17
M03(m)
M02(m)
M04(m)
M05(s) M01(br. s.)
7
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0
6
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TG52 PROTON.esp
8 7 6 5 4 3 2 1 0 -1
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
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0.8
0.9
N
o
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a
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e
d
 I
n
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n
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y
3.841.806.212.00
M02(s)
M03(dd)
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TG53 proton.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
N
o
rm
a
liz
e
d
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n
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n
s
it
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4.061.944.024.00
M03(m)
M01(s)
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TG102 PROTON.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
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n
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n
s
it
y
3.891.844.001.912.29
M04(m)
M03(m)
M01(br. s.)
M05(m)
M02(br. s.)
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TG66 proton.esp
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
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n
s
it
y
4.001.882.622.622.66
J(M05)=6.82 Hz
J(M04)=8.34 Hz
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M03(br. s.)
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TG67 PROTON.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
N
o
rm
a
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e
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4.442.034.814.00
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TG60.001.001.1r.esp
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
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0.7
0.8
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o
rm
a
liz
e
d
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n
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6.453.891.884.002.221.92
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TG105 PROTON.esp
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
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o
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a
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6.404.022.106.002.05
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TG74.PROTON.esp
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
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0.8
0.9
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o
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a
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6.883.711.764.434.00
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TG104 PROTON.esp
8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
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4.632.144.312.002.33
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TG58 PROTON.esp
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13C NMR Spectra 
13C NMR Spectrum for Compound 2a 
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13C NMR Spectrum for Compound 2b 
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TG32-1 Third spot orange oil Carbon.esp
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TG24 carbon.esp
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13C NMR Spectrum for Compound 8c 
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13C NMR Spectrum for Compound 8d 
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13C NMR Spectrum for Compound 8e 
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13C NMR Spectrum for Compound 8f 
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13C NMR Spectrum for Compound 8g 
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13C NMR Spectrum for Compound 8h 
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13C NMR Spectrum for Compound 8i 
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13C NMR Spectrum for Compound 8j 
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13C NMR Spectrum for Compound 14a 
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13C NMR Spectrum for Compound 14b 
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13C NMR Spectrum for Compound 14c 
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13C NMR Spectrum for Compound 14d 
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Mass Spectra 
 
Mass Spectra for compound 2a 
  
in MeOH 100x dilution 01-Jul-201312:44:58
m/z
100 150 200 250 300 350 400 450 500 550 600
%
0
100
THERESA_TG12-1_MOORING-ACCU_07012013_ESI-POS02 64 (1.193) AM (Top,2, Ar,5000.0,0.00,1.00); Sm (SG, 2x3.00); Cm (54:64)
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Mass Spectra for compound 2b 
  
TG_99_ESIPOS_MOORING_05202015_150520142143 #213-221 RT: 2.98-3.09 AV: 9 NL: 1.68E9
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 2c 
  
TG34_ESIPOS_MOORING_041317 #217-226 RT: 3.00-3.13 AV: 10 NL: 1.38E8
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for compound 2d 
Therasa_TG32_ESI_pos_Mooring_04032014_2 #3 RT: 0.01 AV: 1 NL: 3.36E7
T: FTMS + c ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 2e 
Theresa_TG78_ESIPOS_Mooring_04292015_150429152657 #186-198 RT: 2.58-2.75 AV: 13 NL: 2.70E9
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 2f 
  
TG_100_MOORING_ESIPOS_021016_160210142315 #150-160 RT: 2.27-2.40 AV: 11 NL: 2.34E8
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 2g 
  
QtofMicro 14-Jan-201416:07:33
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
THERESA_TG22_MOORING-ACCU_01142014_ESI-POS01 19 (0.354) AM (Cen,2, 80.00, Ar,5000.0,0.00,1.00); Sm (Mn, 2x3.00); Cm (13:19)
1.49e5346.2291
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Mass Spectra for compound 2h 
  
TG_98_ESIPOS_MOORING_05202015_150520140416 #203-211 RT: 2.83-2.94 AV: 9 NL: 2.02E9
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 2i 
  
in MeOH 100x dilution 01-Jul-201313:00:28
m/z
100 150 200 250 300 350 400 450 500 550 600
%
0
100
THERESA_TG13-1_MOORING-ACCU_07012013_ESI-POS01 54 (1.006) AM (Cen,2, 80.00, Ar,5000.0,0.00,1.00); Sm (SG, 2x3.00); Cm (51:60)
6.93e3326.1462
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Mass Spectra for compound 2j 
  
in MeOH+0.1%HCOOH  556.2771 10:26:20  15-Mar-2013
m/z
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THERESA_GG7_HR_ESI_POS_MOORING_03152013_1 181 (3.610) AM (Cen,2, 80.00, Ar,5000.0,556.28,0.70); Cm (177:201)
1.70e4417.2165
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Mass Spectra for compound 2k 
Theresa_TG83_ESIPOS_Mooring_04292015 #189-195 RT: 2.57-2.65 AV: 7 NL: 1.18E9
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 2l 
 
Theresa_TG16-1_Mooring-ACCU_08272013_ESI-POS #165-169 RT: 2.25-2.30 AV: 5 SB: 8
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 2m 
  
Theresa_TG17-1_Mooring-ACCU_08272013_ESI-POS_130827185100 #168-173 RT: 2.29-2.36
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 2n 
  
QtofMicro 14-Jan-201416:35:55
m/z
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%
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THERESA_TG24_MOORING-ACCU_01142014_ESI-POS01 41 (0.766) AM (Cen,2, 80.00, Ar,5000.0,0.00,1.00); Sm (Mn, 2x3.00); Cm (35:41)
1.69e4350.1862
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Mass Spectra for compound 2o 
  
TG93_FLUSH_ESIPOS_MOORING_06172015 #183-189 RT: 2.50-2.58 AV: 7 NL: 8.45E7
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 2p 
  
in MeOH 100x dilution 01-Jul-201313:05:37
m/z
100 150 200 250 300 350 400 450 500 550 600
%
0
100
THERESA_TG14_MOORING-ACCU_07012013_ESI-POS01 86 (1.590) AM (Cen,2, 80.00, Ar,5000.0,0.00,1.00); Cm (75:87)
1.69e4350.1865
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Mass Spectra for compound 2q 
  
Theresa_TG90_ESIPOS_Mooring_04292015 #181-187 RT: 2.49-2.57 AV: 7 NL: 2.48E9
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 2r 
Therasa_TG29_ESI_pos_Mooring_04032014_1 #1 RT: 0.01 AV: 1 NL: 1.15E9
T: FTMS + c ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 2s 
  
Therasa_TG28_ESI_pos_Mooring_04032014_1 #68 RT: 0.49 AV: 1 NL: 3.11E7
T: FTMS + c ESI Full ms [100.00-1000.00]
100 200 300 400 500 600 700 800 900 1000
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
426.1381
234 
 
 
Mass Spectra for compound 2t 
  
Theresa_TG37_ESIPOS_Mooring_04232014_3 #120 RT: 1.64 AV: 1 NL: 3.40E8
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 2u 
  
QtofMicro 14-Jan-201416:14:28
m/z
376 377 378 379 380 381 382 383 384 385 386 387 388 389 390
%
0
100
THERESA_TG19_MOORING-ACCU_01142014_ESI-POS01 17 (0.317) AM (Cen,2, 80.00, Ar,5000.0,0.00,1.00); Sm (Mn, 2x3.00); Cm (17:78)
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Mass Spectra for compound 2v 
  
QtofMicro 14-Jan-201415:56:23
m/z
378 379 380 381 382 383
%
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THERESA_TG18_MOORING-ACCU_01142014_ESI-POS01 5 (0.093) AM (Cen,2, 80.00, Ar,5000.0,0.00,1.00); Sm (Mn, 2x3.00); Cm (3:8)
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Mass Spectra for compound 2w 
  
TG33__ESIPOS_MOORING_072716 #109-184 RT: 1.72-2.82 AV: 76 NL: 5.56E6
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 2x 
Theresa_TG39_ESIPOS_Mooring_05142014_2 #71 RT: 0.96 AV: 1 NL: 1.50E7
T: FTMS + c ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 4a 
  
Theresa_TG50_ESIPOS_Mooring_061114 #169 RT: 2.39 AV: 1 NL: 2.49E7
T: FTMS + p ESI Full ms [200.00-2000.00]
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Mass Spectra for compound 4b 
  
GAINES_103_ESIPOS_MOORING_062415 #158-234 RT: 2.15-3.20 AV: 77 NL: 2.63E5
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 4c 
  
QtofMicroin ACN+0.1%HCOOH 556.2771 as ITSD 23-Jun-201416:18:29
m/z
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%
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THERESA_TG54_HR_ESIPOS_MOORING_062314 300 (5.578) AM (Cen,4, 80.00, Ar,6000.0,556.28,0.80)
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Mass Spectra for compound 4d 
  
TG_55_ESIPOS_MOORING_070516 #136-143 RT: 1.93-2.02 AV: 8 NL: 4.20E5
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for compound 4e 
GAINES_107_ESIPOS_MOORING_06242015 #203-210 RT: 2.77-2.87 AV: 8 NL: 1.12E6
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 4f 
  
GAINES_108_ESIPOS_MOORING_06242015 #188-193 RT: 2.56-2.63 AV: 6 NL: 2.01E6
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 4g 
  
Theresa_BG51_ESIPOS_Mooring_061114 #154 RT: 2.19 AV: 1 NL: 5.38E7
T: FTMS + p ESI Full ms [200.00-2000.00]
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Mass Spectra for compound 4h 
  
TG_101_ESIPOS_MOORING_05202015_150521100830 #205-224 RT: 2.90-3.16 AV: 20 NL: 7.61E6
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 4i 
  
Theresa_TG52_ESIPOS_POS_Mooring_061214 #207 RT: 2.91 AV: 1 NL: 9.58E6
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 4j 
  
Theresa_TG53_ESIPOS_Mooring_061214 #195 RT: 2.73 AV: 1 NL: 1.73E7
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 4k 
GAINES_102_ESIPOS_MOORING_062415 #168-220 RT: 2.29-3.01 AV: 53 NL: 5.96E5
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 4l 
TGraines_TG66_ESIPOS_Mooring_100182014_1 #171 RT: 2.42 AV: 1 NL: 4.04E6
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 4m 
  
TGraines_TG67_ESIPOS_Mooring_100182014_1 #168 RT: 2.38 AV: 1 NL: 1.65E6
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 4n 
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Mass Spectra for compound 4o 
  
GAINES_105_ESIPOS_MOORING_062415 #158-199 RT: 2.15-2.72 AV: 42 NL: 1.24E7
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 4p 
  
TG74_ESIPOS_MOORING_041217 #120-137 RT: 1.70-1.93 AV: 18 NL: 1.45E6
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for compound 4q 
TG104_ESIPOS_MOORING_041217 #144-168 RT: 2.03-2.37 AV: 25 NL: 1.91E5
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for compound 4r 
  
TG58_ESIPOS_MOORING_041217 #163-173 RT: 2.28-2.41 AV: 11 NL: 3.59E6
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for compound 4s 
  
TG_59_ESIPOS_MOORING_070516 #129-143 RT: 1.83-2.03 AV: 15 NL: 3.10E3
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for compound 4t 
  
TG_75_ESIPOS_MOORING_070516 #112-116 RT: 1.59-1.64 AV: 5 NL: 3.36E5
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for compound 4u 
  
TG111_ESIPOS_MOORING_041217 #114 RT: 1.61 AV: 1 NL: 2.04E7
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for compound 8a 
  
261 
 
 
Mass spectra for compound 8b 
 
TG_64_ESIPOS_MOORING_071217 #319-325 RT: 4.50-4.59 AV: 7 NL: 4.70E5
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass spectra for compound 8c 
 
 
 
TG_65_ESIPOS_dil_MOORING_071217_1_170713094936 #84-107 RT: 1.19-1.52 AV: 24 NL: 5.18E3
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for compound 8d 
  
Theresa_TG36_ESIPOS_Mooring_04232014_2 #6-7 RT: 0.08-0.09 AV: 2 NL: 9.56E7
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 8e 
TG10_ESIPOS_MOORING_041217 #138-147 RT: 1.95-2.07 AV: 10 NL: 1.62E7
T: FTMS + p ESI Full ms [50.00-1000.00]
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Mass Spectra for compound 8f 
Theresa_TG8_ESIPOS_Mooring_04232014_2 #75 RT: 1.01 AV: 1 NL: 2.82E8
T: FTMS + p ESI Full ms [150.00-2000.00]
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Mass Spectra for compound 8g 
TGraines_TG68_ESIPOS_Mooring_100182014 #175 RT: 2.48 AV: 1 NL: 1.01E7
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 8h 
TGraines_TG69_ESIPOS_Mooring_100182014 #162 RT: 2.29 AV: 1 NL: 1.24E7
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 8i 
  
Theresa_TG62_ESIPos_Mooring_09102014 #183 RT: 2.60 AV: 1 NL: 2.23E7
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 8j 
Theresa_TG63_ESIPos_Mooring_09102014 #195 RT: 2.77 AV: 1 NL: 3.06E7
T: FTMS + p ESI Full ms [100.00-1000.00]
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Mass Spectra for compound 14a 
  
Theresa_TG42_ESIPOS_Nooring_06111401 #104-234 RT: 1.48-3.27 AV: 131 NL: 2.05E8
T: FTMS + p ESI Full ms [200.00-2000.00]
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Mass Spectra for compound 14b  
Theresa_TG46_ESIPOS_Mooring_061114 #217 RT: 3.02 AV: 1 NL: 7.45E7
T: FTMS + p ESI Full ms [200.00-2000.00]
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Mass Spectra for compound 14c 
  
Theresa_TG43_ESIPOS_Mooring_06112014 #104-234 RT: 1.48-3.27 AV: 131 NL: 6.65E7
T: FTMS + p ESI Full ms [200.00-2000.00]
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Mass Spectra for compound 14d 
 
 
 
 
 
 
Theresa_TG45_ESIPOS_Mooring_061114 #279 RT: 3.87 AV: 1 NL: 8.33E7
T: FTMS + p ESI Full ms [200.00-2000.00]
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